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Parkinson’s disease 
Parkinson’s disease (PD) has typically been characterized as a progressive 
movement disorder, but it is nowadays recognized that non-motor domains are 
involved as well (Chaudhuri et al., 2006). Essential for diagnosis is parkinsonism, 
which is defined as bradykinesia plus resting tremor or rigidity (Postuma et al., 
2015). Recent criteria for the diagnosis of PD also take non-motor symptoms into 
account (Postuma et al., 2015). Non-motor features, such as cognitive impairment, 
autonomic dysfunction, depression, nighttime sleep problems, daytime sleepiness 
and hyposmia, may already appear before the first clinical motor symptoms 
emerge (Adler and Beach, 2016; Chaudhuri et al., 2006). PD patients show 
considerable variability in their clinical expression and progression rate of the 
disease, response to treatment and extent to which different pathological 
pathways are involved (Foltynie et al., 2002; Linazasoro, 2007). 
The cardinal motor symptoms of PD (i.e. bradykinesia, tremor, rigidity) are 
linked to the loss of dopaminergic neurons in the substantia nigra pars compacta 
(Damier et al., 1999), but neuropathological changes of PD extend far beyond the 
nigrostriatal system, affecting also noradrenergic, serotonergic, cholinergic and 
other neurotransmitter systems (Wolters, 2008). Alpha-synuclein aggregates 
(including Lewy bodies and Lewy neurites) are demonstrated in the central, 
peripheral and autonomic nervous system, and likely contribute to the various non-
motor symptoms of PD (Adler and Beach, 2016). However, other protein deposits 
including tau and amyloid beta have been identified in PD (Kalaitzakis et al., 2008). 
The identification of distinct PD subtypes may provide insights into the 
underlying pathophysiology, aid in the prediction of progression or offer guidance 
in developing more efficient personalized care approaches. Various studies have 
attempted to address heterogeneity in PD with classification systems, often based 
on clinical characteristics of patients, such as a tremor or postural-instability-and-
gait disorder dominant phenotype (Mestre et al., 2018). The reproducibility of 
these classification systems is problematic. For instance, patients may switch from 
one subtype to another, due to changing clinical presentations (Mestre et al., 2018; 
Simuni et al., 2016). Besides classification based on a particular clinical trait, the 
differentiation of PD subtypes might also be based on the use of other disease 
features such as molecular or imaging markers (Drysdale et al., 2017). Recent 
research in depression, which is, like PD, not a uniform disease, identified subtypes 
defined by distinct patterns of connectivity on resting-state functional magnetic 
resonance imaging (fMRI) scans (Drysdale et al., 2017). Although these subtypes 
are based on distinct functional connectivity patterns, they appear associated with 
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certain clinical features and predict responsiveness to certain types of therapy 
(Drysdale et al., 2017). 
 
Lewy Body Dementia 
Patients with dementia with Lewy bodies (DLB) show important similarities with PD 
patients both in pathology as well as in clinical characteristics, such as the presence 
of Lewy bodies and symptoms of parkinsonism, but the progression rate, disease 
course and phenotype are different from patients with PD. Although DLB patients 
meeting the full criteria for PD may now be qualified as PD (DLB subtype) (Postuma 
et al., 2015), the progressive invalidating course of DLB and the decreased efficacy 
and tolerance of medication as compared to PD underscore the necessity of a clear 
distinction between the two in the early phase, which is at present still very difficult.  
 
Neuroimaging 
Neuroimaging offers the opportunity to study disease-related changes of the brain 
and the possibility to link pathology to clinical manifestations in a non-invasive 
manner. Many studies have evaluated conventional MRI techniques in PD, such as 
voxel-based morphometry, by using T1-weighted images (Pan et al., 2012). These 
studies have revealed reduced brain grey matter in PD patients (Pan et al., 2012); 
however, no PD-specific grey matter atrophy patterns have been identified so far. 
Several studies have studied substantia nigra volumetric differences on MRI, but 
with heterogeneous results as well. Some studies report no volumetric differences 
in the substantia nigra compared to control subjects, whereas others identified a 
decrease and still others even an increase in volume (Saeed et al., 2017). 
High-field MRI as well as new imaging techniques became available since 
initial MRI studies in PD. Advanced neuroimaging techniques include diffusion-
weighted imaging (DWI), magnetization transfer imaging (MTI) and fMRI. DWI can 
provide quantitative measures of the microstructural integrity of white matter. The 
concept of DWI is based on random (isotropic) movement of water molecules, 
without constraints. Diffusion of water molecules is usually not random, but 
restricted (anisotropic) by the surrounding architecture such as fiber tracts. 
Diffusion tensor imaging (DTI) can estimate anisotropy to provide directional 
information, or can measure the overall movement of molecules (mean diffusivity). 
MTI can be used to detect changes in brain structures that may not be visible with 
standard MR techniques by measuring magnetization transfer between free 
protons and protons bound to macromolecules. fMRI can yield important 
information on the brain’s functional connectivity. It measures blood oxygen level 
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dependent (BOLD) signal fluctuation in the brain in response to a particular task or 
stimuli, or spontaneous BOLD fluctuations at rest, which is called resting-state fMRI 
(Fox and Raichle, 2007).  
These advanced techniques have already shown promising results in PD. 
Recent studies suggest that DTI of the substantia nigra might become a valuable 
tool to monitor PD progression, or to distinguish PD patients from control subjects 
(Burciu et al., 2017; Ofori et al., 2017; Vaillancourt et al., 2009). However, it remains 
to be determined how these techniques can be applied to clinical practice for 
individual patients, as the results often represent group-wise differences between 
PD patients and control subjects. Further, only a limited number of studies have 
used these advanced MRI techniques in PD so far, and most of these studies have 
focused on specific patient subgroups and pre-defined regions of interest, the 
latter often dopamine-related structures. As we have come to appreciate that PD 
affects both grey matter areas and white matter tracts throughout the entire brain 
(Lim et al., 2009), it is important that more studies investigate the whole brain. 
 
Brain networks 
Network approaches may help to assess the widespread consequences of disease-
specific changes in neurodegenerative diseases as PD. A common method to 
segment the brain functionality into sub-networks is independent component 
analysis. Resting-state networks represent spatial distinct regions with co-varying 
BOLD (as measured with resting-state fMRI) signals at rest. Previous fMRI studies 
revealed a number of networks which are consistently found across subjects, and 
which show remarkable correspondence to patterns of task activation (Beckmann 
et al., 2005; Damoiseaux et al., 2006). The default mode network, for example, is 
a frequently studied resting-state network in neurodegenerative diseases. Graph 
analytical methods can be used to investigate the global organization of the whole-
brain functional connectivity network (i.e. the functional connectome). A relatively 
new method in the field of graph-based methods is eigenvector centrality mapping 
(ECM). ECM does not require a-priori knowledge, identifies prominent regions in 
the whole brain network hierarchy and detects localized differences between two 
populations (Wink et al., 2012).  
In addition to functional network approaches, evidence suggests that 
anatomical structures that are spatially distributed but functionally linked, co-vary 
in grey matter density within individuals across a population (Alexander-Bloch et 
al., 2013; Andrews et al., 1997). The grouping of these structures, so-called 
structural covariance networks (SCNs), are increasingly important in uncovering in 
  General introduction | 1 
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vivo patterns of brain atrophy not readily apparent by regional structural analysis 
(Alexander-Bloch et al., 2013; Hafkemeijer et al., 2016, 2014). It was shown that 
Alzheimer's disease and frontotemporal dementia have specific SCNs of 
degeneration (Hafkemeijer et al., 2016) and distinct aging effects were further 
demonstrated on the organization of SCNs in healthy elderly (Montembeault et al., 
2016; Spreng and Turner, 2013). Regarding the results in other neurodegenerative 
diseases, it could be valuable to study SCNs in PD.  
 
Profiling Parkinson’s disease 
This cross-sectional cohort study is part of the Profiling Parkinson's disease 
(PROPARK) study. PROPARK research has resulted in the establishment of an 
extensive database of over 400 well-characterized patients which formed the basis 
for several projects on clinical characterization, inter-relations between clinical 
domains, phenotype-genotype relations and the neuroimaging study described in 
this thesis. Previous PROPARK research has also led to identification of a coherent 
grouping of some of the clinical domains in PD, largely involving symptoms that do 
not improve on dopaminergic medication. The severity of non-dopaminergic 
symptoms in Parkinson’s disease (SENS-PD) scale is a composite score comprising 
the following six domains: postural instability and gait difficulty, psychotic 
symptoms, excessive daytime sleepiness, autonomic dysfunction, cognitive 
impairment and depressive symptoms. The grouping of these clinical domains is 
present early in the disease course (van der Heeden et al., 2016, 2014), worsens 
over time (van der Heeden et al., 2016, 2014) and may reflect advancing Lewy body 
pathology in the nervous system (Adler and Beach, 2016). Given the multisystem 
nature of PD and the increasing evidence of the importance of predominantly non-
dopaminergic domains during the course of PD, the use of the SENS-PD scale 
could lead to a more complete and accurate evaluation of disease severity. 
 
Aims of this thesis 
The general aim of this thesis was to apply advanced neuroimaging approaches 
that may identify changes that are characteristic of PD, aid in the differentiation of 
potential PD subtypes, and contribute to the differentiation of PD and DLB. To this 
end, we searched for differential brain MRI features in PD patients compared to 
healthy control subjects, and examined the relations between these features and 
patient characteristics, such as age, dopaminergic medication, motor and 
predominantly non-dopaminergic impairments.  
General introduction | 1 
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We started analyzing T1-weighted brain images in chapter 2 and 3. In 
chapter 2, we studied SCNs of grey matter in PD patients that had earlier been 
established in healthy elderly. We evaluated whether the integrity of SCNs is 
associated with clinical severity of PD, and whether SCNs showed a loss of integrity 
beyond the effect of aging that was shown in the normal population. In chapter 3, 
we assessed if studying structural characteristics of grey matter, including SCNs, 
may contribute in differentiating DLB and PD more clearly. We studied white 
matter integrity in chapter 4, using T1-weighted, fluid-attenuated inversion 
recovery (FLAIR), DWI and MTI brain images. We hypothesized that the decline in 
white matter integrity is significantly greater in PD patients than seen in healthy 
aging subjects and that there may be an age-by-PD interaction effect on white 
matter integrity. To this end, we compared macro- and microstructural integrity 
parameters of global white matter between PD patients and control subjects. In 
chapter 5 and 6, we studied resting-state fMRI data. The aim of chapter 5 was to 
evaluate and compare the consequences of PD on the resting-state functional 
connectivity on a whole-brain level of integrated networks (ECM) and on eight 
explicit brain networks. Finally, we aimed to use resting-state fMRI data for 
classification of PD on an individual patient level in chapter 6. In chapter 7 all 
findings are briefly summarized after which the potential future directions of MRI 
research in PD are discussed.
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ABSTRACT 
 
Introduction: In Parkinson's disease (PD), the relation between cortical brain 
atrophy on MRI and clinical progression is not straightforward. Determination of 
changes in structural covariance networks - patterns of covariance in grey matter 
density - has shown to be a valuable technique to detect subtle grey matter 
variations. We evaluated how structural network integrity in PD is related to clinical 
data.  
 
Methods: 3 Tesla MRI was performed in 159 PD patients. We used nine 
standardized structural covariance networks identified in 370 healthy subjects as a 
template in the analysis of the PD data. Clinical assessment comprised motor 
features (Movement Disorder Society unified Parkinson's Disease rating scale; 
MDS-UPDRS motor scale) and predominantly non-dopaminergic features (severity 
of non-dopaminergic symptoms in Parkinson's disease; SENS-PD scale: postural 
instability and gait difficulty, psychotic symptoms, excessive daytime sleepiness, 
autonomic dysfunction, cognitive impairment and depressive symptoms). Voxel-
based analyses were performed within networks significantly associated with PD. 
  
Results: The anterior and posterior cingulate network showed decreased integrity, 
associated with the SENS-PD score, p = 0.001 (b = −0.265, hp2 = 0.070) and p = 
0.001 (b = −0.264, hp2 = 0.074), respectively. Of the components of the SENS-PD 
score, cognitive impairment and excessive daytime sleepiness were associated with 
atrophy within both networks.  
 
Conclusion: We identified loss of integrity and atrophy in the anterior and posterior 
cingulate networks in PD patients. Abnormalities of both networks were associated 
with predominantly non-dopaminergic features, specifically cognition and 
excessive daytime sleepiness. Our findings suggest that (components of) the 
cingulate networks display a specific vulnerability to the pathobiology of PD and 
may operate as interfaces between networks involved in cognition and alertness. 
 Structural covariance networks in PD | 2 
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INTRODUCTION 
Parkinson's disease (PD) is characterized by a broad spectrum of motor and non-
motor features. It has been proposed that widespread pathological changes (Lewy 
bodies and Lewy neurites) in select nuclei of the central and peripheral nervous 
system underlie the complex clinical presentation of PD (Jellinger, 2012). 
Increasing evidence points at the existence of a coherent grouping of some of the 
clinical domains, which largely involve symptoms that do not improve on 
dopaminergic medication. The grouping of these symptoms is present early in the 
disease course (van der Heeden et al., 2016), worsens over time (van der Heeden 
et al., 2016), and probably reflects advancing Lewy body pathology in the nervous 
system (Adler and Beach, 2016).  
Previous anatomical magnetic resonance imaging (MRI) studies commonly 
investigated voxel-wise differences in regional grey matter volume between PD 
patients and control subjects. These studies revealed reduced grey matter in 
patients (Pan et al., 2012), which, however, is nonspecific to PD. Further, the 
findings are inconsistent across studies (Pan et al., 2012), which is likely explained 
by the clinical heterogeneity of PD and the current insensitivity of imaging 
techniques to detect subtle changes in brain structures. New techniques including 
computational network-based analyses are increasingly important in uncovering in 
vivo patterns of brain atrophy not readily apparent by regional structural analysis 
(Alexander-Bloch et al., 2013; Hafkemeijer et al., 2016). Evidence suggests that 
anatomical structures that are spatially distributed but functionally linked, co-vary 
in grey matter density (structural covariance networks; SCNs) within individuals 
across a population (Alexander-Bloch et al., 2013; Andrews et al., 1997).  
Factors like age and disease affect SCNs (Hafkemeijer et al., 2014; Möller 
et al., 2015). Distinct aging effects on the organization of SCNs were demonstrated 
in healthy elderly (Montembeault et al., 2012; Spreng and Turner, 2013). Also, it 
was shown that Alzheimer’s disease and frontotemporal dementia have specific 
SCNs of degeneration (Hafkemeijer et al., 2016). These findings support that this 
methodology may have the potential to identify brain regions within disease 
specific structural networks that confer a preferential vulnerability to the 
pathobiology of PD. 
In this study, we studied SCN integrity in PD patients. We evaluated 
whether the integrity of SCNs (constructed from grey matter density in healthy 
elderly adults), is associated with clinical severity of PD and if the integrity is 
associated with predominantly dopaminergic or nondopaminergic symptoms. 
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MATERIALS AND METHODS 
Study design and Participants 
PD patients were recruited from the outpatient clinic for Movement Disorders of 
the Department of Neurology of the LUMC (Leiden University Medical Center) and 
nearby university and regional hospitals. All participants fulfilled the United 
Kingdom Parkinson’s Disease Society Brain Bank criteria for idiopathic PD (Gibb 
and Lees, 1988). The present study is a cross-sectional cohort study of PD patients 
and is part of the Profiling Parkinson's disease (PROPARK) study. Written consent 
was obtained from all participants. The Medical Ethics Committee of the LUMC 
approved the study. 
 
Clinical assessments 
All patients underwent standardized assessments, including an evaluation of 
demographic and clinical characteristics. Participants were tested while on 
medication, except for 24 patients (22 de novo patients, defined as dopaminergic 
drug-naïve patients with a disease duration shorter than five years; two other 
dopaminergic drug-naïve patients). The Movement Disorder Society unified 
Parkinson's disease rating scale (MDS-UPDRS) part III (motor scale) was used to 
quantify the severity of motor symptoms. The severity of non-dopaminergic 
symptoms in Parkinson's disease (SENS-PD) scale is a composite score comprising 
three items with four response options (0–3) from each of the following six 
predominantly non-dopaminergic domains: postural instability and gait difficulty, 
psychotic symptoms, excessive daytime sleepiness, autonomic dysfunction, 
cognitive impairment and depressive symptoms (total range: 0–54) (van der 
Heeden et al., 2016, 2014). These six domains represent a coherent complex of 
symptoms that is already present in the early disease stages and increases in 
severity when the disease advances. The SENS-PD is a recently developed short, 
reliable and valid scale that includes symptoms that do not improve with 
dopaminergic medication and its score may therefore more accurately reflect 
severity and progression of the underlying disease than currently used dopamine-
sensitive measures. Higher scores on both scales reflect more severe impairment. 
Trained research associates administered the MDS-UPDRS motor scale and the 
“postural instability and gait difficulty”, “psychotic symptoms” and “cognitive 
impairment” items of the SENS-PD scale. The “excessive daytime sleepiness”, 
“autonomic dysfunction” and “depressive symptoms” items were self-completed 
by patients. A levodopa dose equivalent (LDE) of daily levodopa and dopamine 
agonists dose was calculated for each patient. The total LDE is the sum of levodopa 
Structural covariance networks in PD | 2 
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dosage equivalent (LDE-Dopa) and the dopamine agonist dosage equivalent (LDE-
DA) (Tomlinson et al., 2010). 
 
MRI acquisition 
Three-dimensional T1-weighted anatomical images were acquired on a 3 Tesla MRI 
scanner (Philips Achieva, Best, the Netherlands) using a standard 32-channel 
whole-head coil. Acquisition parameters were: repetition time = 9.8 ms, echo time 
= 4.6 ms, flip angle = 8°, field of view 220 × 174 × 156 mm, 130 slices with a slice 
thickness of 1.2 mm with no gap between slices, resulting in a voxel size of 1.15 
mm × 1.15 mm × 1.20 mm. 
 
Data analysis  
Before analysis, all MRI scans were visually checked to ensure that no major artifacts 
or abnormalities were present in the data. All analyses were done using the 
software provided by FMRIB’s software library (FSL, version 5.0.8, Oxford, United 
Kingdom) (Smith et al., 2004).  
 
Pre-processing 
The three-dimensional T1 images were pre-processed using the pre-processing 
steps used for voxel-based morphometric analysis (Douaud et al., 2007; Good et 
al., 2001; Smith et al., 2004). Each step was visually checked. The T1-weighted 
images were brain-extracted and tissue-type segmentation was performed, 
resulting in probability maps of a given tissue type (i.e. grey matter, white matter 
or cerebrospinal fluid). The grey matter images were non-linearly registered to the 
2 mm Montreal Neurological Institute (MNI) 152 standard space (Montreal 
Neurological Institute, Montreal QC, Canada) (Andersson et al., 2007; Jenkinson 
et al., 2002a). The resulting images were averaged to create a study-specific grey 
matter template. All native grey matter images were subsequently nonlinearly re-
registered to the study-specific grey matter template and “modulated” to correct 
for local expansions or contractions due to the non-linear component of the spatial 
transformation. The images were smoothed with an isotropic Gaussian kernel with 
a sigma of 3 mm. The modulated grey matter images in MNI space were 
concatenated into a four-dimensional data set, which was used for the network and 
voxel-based morphometry (VBM) analyses. 
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Structural covariance networks 
We used nine bilateral standardized SCNs, identified in 370 healthy elderly with an 
age range of 45–85 years, which is the same as the age range in our PD population. 
For detailed information on the networks see Hafkemeijer et al. (2014). The 
networks were derived using an independent component analysis, a statistical 
technique that defines spatial component maps of maximal statistical 
independence. It is commonly used to study functional network integrity, but it can 
also be used to study if brain structures of a population co-vary in grey matter 
volume (Hafkemeijer et al., 2014; Segall et al., 2012). The four-dimensional data set 
of grey matter images derived from our PD population was used in a spatial 
regression against the nine SCN probability maps (a general linear model approach 
integrated in FSL) (Filippini et al., 2009). This way individual SCN integrity scores 
were calculated. The integrity score is the beta coefficient of the regression 
analysis. It can be a negative or a positive score, reflecting the strength of the 
individual expression in each network, with high scores indicating strong individual 
expression of the network. To allow comparisons of the SCNs of the template and 
of patients with PD, identification of the nine SCNs in patients with PD was 
conducted using the same approach as Hafkemeijer et al. (2014). An independent 
component analysis was applied on the four-dimensional data set of modulated 
grey matter images of all PD patients, using multivariate exploratory linear 
optimized decomposition into independent components (Beckmann et al., 2005). 
The independent component analysis was restricted to nine components, the same 
amount as in the study of Hafkemeijer et al. (2014). Significance of individual voxels 
within a spatial map was derived using a mixture model, with a standard threshold 
level of 0.5 (Smith et al., 2004), which indicates an equal loss is placed on false 
positives and false negatives.  
 
Voxel-based morphometry 
To investigate group differences in grey matter volume, a voxel-wise general linear 
model in FSL was used. Grey matter region-of-interest masks were obtained by 
identifying anatomical structures that were present in the SCNs (Hafkemeijer et al., 
2014). A design matrix was constructed for estimating the relationship between 
grey matter volume (in each region-of-interest) and clinical measures. Gender, age 
and disease duration were used as covariates to correct for confounding effects. 
The voxel-wise general linear model was applied on the previously derived four-
dimensional data set. Randomise, FSL's tool for nonparametric permutation 
inference on neuroimaging data, was used with 5000 permutations to perform non-
Structural covariance networks in PD | 2 
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parametric statistics (Winkler et al., 2014). We used the threshold-free cluster 
enhancement (TFCE) technique to correct for multiple comparisons (Smith and 
Nichols, 2009). Brain structures were identified using the Harvard-Oxford atlas 
integrated in FSL. 
 
Statistical analysis 
Differences in age and gender between patients and control subjects in which the 
template was defined, were analyzed with an independent sample t-test (age) and 
a chi-square test (gender). The relationship between SCN integrity and clinical 
measures was investigated using general linear modeling within the PD group, 
adjusted for gender, age and disease duration. Associations were studied between 
SCN integrity scores (dependent variable) and the MDS-UPDRS motor score, and 
between SCN integrity scores and the SENS-PD score. Bonferroni correction was 
applied to account for multiple comparisons (p-value: 0.05/18 = 0.003). If the 
integrity score of a network showed a statistically significant association with the 
MDS-UPDRS motor score or the SENS-PD score, we examined associations 
between the SCN integrity score and the domains scores of the concerning clinical 
scale. A Bonferroni correction was applied across the different networks (p-value = 
0.05/number of items of the concerning clinical score, i.e. six domains of the SENS-
PD and four of the MDS-UPDRS motor score). To investigate whether dosage of 
dopaminergic medication could affect structural networks, we examined 
associations between the SCN integrity scores and LDE scores within the PD group 
who used dopaminergic medication. To study group differences between de novo 
patients and patients who used dopaminergic medication, we performed 
additional general linear modeling analyses in which network integrities were 
treated as dependent variables and the group (de novo patients or patients who 
used dopaminergic medication) as an independent, fixed, variable, while adjusting 
for age and gender. SPSS version 23.0 was used for all analyses (IBM SPSS Statistics 
for Mac, Version 23.0. Armonk, NY: IBM Corp.). 
 
RESULTS 
Demographic characteristics 
159 patients were included in the analysis. Demographic and clinical data of all 
participants are shown in table 1. 
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Structural covariance network integrity 
Of the nine SCNs, the integrity of the posterior and anterior cingulate network 
(SCN c and d) both showed a negative association with the SENS-PD score (p = 
0.001 and p = 0.001, respectively; table 2). The integrity of the anterior cingulate 
network showed a negative association with the MDS-UPDRS motor score (p = 
0.032). After correction for multiple comparisons, the associations between the 
posterior and anterior cingulate network and the SENS-PD score remained 
significant (table 2).  
As the associations between the posterior and anterior cingulate network 
and the total SENS-PD score were significant, the associations between SCN 
integrity of the cingulate networks and the domain scores of the SENS-PD scale 
(postural instability and gait difficulty, cognitive impairment, depressive symptoms, 
psychotic symptoms, excessive daytime sleepiness and autonomic symptoms) were 
subsequently tested. The SCN integrity scores of the posterior and anterior 
cingulate network were negatively associated with cognitive impairment (posterior 
cingulate network: b = −0.309, p < 0.001, hp2 = 0.097; anterior cingulate network: 
b = −0.162, p = 0.049, hp2 = 0.026) and excessive daytime sleepiness (posterior 
Table 1. Main characteristics of participants 
 Patients Control subjects  
N 159 370 P-value 
Men/women 101/58 (63.5) 178/ 192 (48.1) 0.001 
Age, year 64.9 (7.1) 65.7 (6.7) 0.234 
Disease duration, year 9.1 (4.8) 
MDS-UPDRS motor score (0-132) 34.3 (15.7) 
SENS-PD, n=153 (0-54) 13.0 (6.1) 
MMSE, n=156 (0-30) 28.4 (1.8) 
Total LDE, mg/day, n=129 1010.2 (561.2) 
Dopaminergic drug-naïve patients, n=2 - 
De novo patientsa, n=22 - 
LDE-Dopa, mg/day, n=154 735.1 (507.5) 
LDE-DA dose, mg/day, n=153 198.0 (216.7) 
Values are means (standard deviation) for continuous variables, numbers for gender (% men). For 
all measurement instruments, the score range is presented in parentheses. SD: standard deviation; 
MDS-UPDRS: Movement Disorder Society unified Parkinson’s disease rating scale; SENS-PD: 
severity of non-dopaminergic symptoms in Parkinson's disease; MMSE: mini-mental state 
examination; LDE: Levodopa dosage equivalent; DA: dopamine agonists. 
a De novo patients were defined as dopaminergic drug-naïve patients with a disease duration 
shorter than five years. 
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cingulate network: b = −0.172, p = 0.021, hp2 = 0.034; anterior cingulate network: 
b = −0.213, p = 0.005, hp2 = 0.051). After correction for multiple comparisons, the 
association between the posterior cingulate network and cognitive impairment 
remained significant. The association between the anterior cingulate network and 
EDS remained significant as well. No significant associations were found between 
the SCN integrity and the domain scores of postural instability and gait difficulty, 
depressive symptoms, psychotic symptoms and autonomic symptoms. The 
associations between SCN integrity and the different domain scores of the MDS-
UPDRS motor scale (i.e., tremor, rigidity, bradykinesia and postural instability and 
gait difficulty) were not tested because no significant associations were found 
between SCN integrity scores and the total MDS-UPDRS motor score after 
correction for multiple comparisons. We found that LDE score was not associated 
with SCN integrity scores. For none of the nine SCNs, a significant group difference 
in SCN integrity score was shown between de novo patients and patients who used 
dopaminergic medication. 
 
Table 2. Associations between the SCN integrity scores and the composite clinical measures 
(MDS-UPDRS motor scale; SENS-PD scale) 
  MDS-UPDRS motor 
score 
SENS-PD 
score  
 
 Predominant brain  
region in SCN 
Beta P-value (ηp2) Beta P-value (ηp2) 
SCN a Thalamus -.052 0.511 (.003)  .040 0.617 (.002) 
SCN b Lateral occipital cortex -.075 0.348 (.006) -.052 0.520 (.003) 
SCN c Posterior cingulate cortex -.155 0.052 (.024) -.264 0.001 (.074)⁎ 
SCN d Anterior cingulate cortex -.172 0.032 (.030) -.265 0.001 (.070)⁎ 
SCN e Temporal pole -.071 0.418 (.004) -.025 0.785 (.001) 
SCN f Putamen  .012 0.879 (.000) .024 0.769 (.001) 
SCN g Cerebellum  .094 0.260 (.008) .087 0.311 (.007) 
SCN h Cerebellum  .119 0.156 (.013) .014 0.868 (.000) 
SCN i Cerebellum  .012 0.891 (.000) .037 0.677 (.001) 
SCN: structural covariance network; MDS-UPDRS: Movement Disorder Society unified Parkinson’s 
disease rating scale; SENS-PD: severity of non-dopaminergic symptoms in Parkinson’s disease. 
Beta: standardized b; hp2: partial eta squared. 
⁎ P-value remained significant after correction for multiple comparisons. All analyses were adjusted 
for age, gender and disease duration. 
 
Voxel-based analyses 
Loss of integrity in a SCN is due to grey matter changes in one or more 
component(s) in the network. To detect which components were specifically 
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atrophied, voxel-based analysis within the posterior and anterior cingulate network 
was performed. We used the domain score of cognitive impairment to examine 
decreased grey matter in the posterior cingulate network and excessive daytime 
sleepiness to examine decreased grey matter in the anterior cingulate network, as 
is shown in figure 1. Large clusters of grey matter volume reductions in the 
posterior cingulate network related to cognitive impairment were localized in the 
posterior cingulate cortex (p = 0.002, peak cluster MNI coordinates: 0, −52, 24, 
voxel size = 509) and the central operculum cortex (p < 0.001, peak cluster MNI 
coordinates: 54, −2, 4, voxel size = 786). Smaller clusters of decreased grey matter 
were found in the subcallosal cortex (p = 0.015, peak cluster MNI coordinates: 0, 
16, −12, voxel size = 103), the parietal operculum cortex (p = 0.046, peak cluster 
MNI coordinates: 38, −22, 18, voxel size = 21) and the posterior middle temporal 
gyrus (p = 0.020, peak cluster MNI coordinates: −58, −34, −10, voxel size = 28). In 
the anterior cingulate network, decreased grey matter related to excessive daytime 
sleepiness was found in the middle frontal gyrus (p = 0.014, peak cluster MNI 
coordinates: 36, 16, 48, voxel size = 191), the frontal medial cortex (p = 0.007, peak 
cluster MNI coordinates: −4, 52, −20, voxel size = 252) and the cuneus (p = 0.013, 
peak cluster MNI coordinates: 2, −86, 18, voxel size = 178). 
 
 
 
Figure 1. Regional grey matter changes in PD patients. Red: Reduced grey matter in the 
posterior cingulate network related to cognitive impairment. Yellow: Reduced grey matter 
in the anterior cingulate network related to excessive daytime sleepiness. Images are 
overlaid on the most informative sagittal, coronal and transversal slices of the MNI (Montreal 
Neurological Institute) standard anatomical image (MNI coordinates are −2, 18, 12). Results 
with a threshold-free cluster enhancement (TFCE)-familywise error (FWE) corrected p-value 
< 0.05 and a voxel size above 30 are shown. 
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Figure 2. Cingulate networks defined in healthy control subjects and in patients. Both 
cingulate networks defined in healthy control subjects and in patients with Parkinson's 
disease, overlaid on the most informative sagittal, coronal and transversal slices of the MNI 
(Montreal Neurological Institute) standard anatomical image (MNI coordinates are 8, −14, 
20). A: Posterior cingulate network. B: Anterior cingulate network. 
 
Cingulate networks in patients with PD                                                          
To visualize the abnormal architecture of both cingulate SCNs, the networks were 
also defined in all patients with PD. As is shown in figure 2, some components of 
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the cingulate networks identified in healthy control subjects are missing in the 
networks identified in patients with PD. These missing components do not 
significantly co-vary in grey matter density with the network. The most prominent 
changes are seen in the anterior (figure 2A and B) and posterior cingulate cortex 
(figure 2A) and the frontal medial cortex (figure 2B). 
 
DISCUSSION 
Within individuals across a population, spatially distributed regions of the brain, 
which are functionally linked, may show a structural covariance of grey matter 
volume. Although the neurobiological underpinnings of SCNs and functional 
covariance network associations are unclear, it has been posited that SCNs reflects 
shared long-term trophic influences within functionally synchronous systems 
(Zielinski et al., 2010). Recently, nine SCNs were established in 370 healthy elderly 
(Hafkemeijer et al., 2014). In four out of nine SCNs (subcortical network, 
sensorimotor network, posterior cingulate network, anterior cingulate network), 
grey matter volume decreased with advancing age. Given the important role of 
age in the development and prognosis of PD, we examined the influence of PD on 
the topological organization of nine SCNs established in healthy elderly. Our study 
led to two main findings: (1) only the anterior and posterior cingulate SCN showed 
a loss of integrity beyond the effects of aging; (2) the reduced integrity of both 
cingulate SCNs was significantly associated with predominantly non-dopaminergic 
domains, including cognitive impairment and excessive daytime sleepiness. 
To unravel if specific regions that make up the SCNs explained the clinical 
associations, we studied grey matter changes within both networks in relation to 
these two predominantly non-dopaminergic domains. The largest clusters of 
decreased grey matter were found in relation to cognitive impairment in two 
regions of the posterior cingulate network: central operculum cortex and posterior 
cingulate cortex. Compared to cognitive impairment, smaller clusters of decreased 
grey matter, albeit still significant associations, were found for excessive daytime 
sleepiness in three regions of the anterior cingulate network: frontal medial cortex, 
middle frontal gyrus and cuneus. Collectively, these findings are in line with those 
of others indicating a role of the cingulate cortex in mediating processes involved 
in cognition and vigilance in patients with PD (Leech and Sharp, 2014; Menon and 
Uddin, 2010; Zielinski et al., 2010).  
Cognitive impairment is an important non-motor feature of PD, which 
reflects the variable and interacting dysfunction in a number of diffusely 
distributed, yet interrelated, neural networks that contribute to distinct cognitive 
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processes (Gratwicke et al., 2015). Compelling evidence shows that structural and 
functional abnormalities of the posterior cingulate cortex are found in neurological 
and psychiatric diseases, e.g. Alzheimer's disease, schizophrenia, autism, 
depression and attention deficit hyperactivity disorder (Leech and Sharp, 2014). 
Congruent with results of other studies in PD, our study shows that abnormalities 
of the posterior cingulate cortex are associated with cognitive impairment 
(Christopher et al., 2015; Leech and Sharp, 2014).  
In PD, excessive daytime sleepiness has been found associated with various 
clinical factors, including cognitive impairment, postural instability and gait 
difficulty, hallucinations, advanced disease, and dopaminergic medication 
(Tholfsen et al., 2015; Zhu et al., 2016). The neurological substrates of excessive 
daytime sleepiness are incompletely understood, but likely involve extended 
subcortical-cortical networks acting to promote arousal and sleep (Brown et al., 
2012). The anterior cingulate network shows spatial overlap with the functional 
connectivity salience network (Seeley et al., 2007). The salience network is 
considered to be involved in the integration of internal and external stimuli, 
supporting the association we found with excessive daytime sleepiness (Seeley et 
al., 2007). Our findings showing involvement of multiple regions of the anterior 
cingulate network, are congruent with those of two other studies showing cortical 
atrophy of occipital and frontal brain regions in PD patients with excessive daytime 
sleepiness as compared to PD patients without excessive daytime sleepiness 
(Gama et al., 2010; Kato et al., 2012).    
Our patients had mild to moderate disease severity and a mean disease 
duration of approximately nine years. In PD, cortical alpha-synuclein aggregation 
occurs in advanced stages and except for the cingulate gyrus, neocortical regions 
have low frequencies of alpha-synuclein aggregation (Beach et al., 2009; Jellinger, 
2012). However, the functional consequences of alpha-synuclein aggregation in the 
brain are unclear and Braak stages are not related to clinical severity of PD (Schulz-
Schaeffer, 2010). Recent evidence proposes that diverse molecular and cellular 
pathologies involved in PD can give rise to common patterns of dysfunction at the 
neural systems level (Gratwicke et al., 2015).  
The finding that reduced anterior and posterior cingulate network integrity 
is associated with two different categories of predominantly non-dopaminergic 
symptoms, may suggest that (components) of both SCNs act as an integrative hub. 
Indeed, it is suggested that both the anterior and posterior cingulate cortex may 
operate as important interfaces between different functional networks involved in 
cognition and alertness (Leech and Sharp, 2014; Menon and Uddin, 2010).  
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Cognition and alertness are regulated by large-scale functional networks, 
consisting of numerous interconnected brain areas, which act (dynamically) in 
concert to perform the circumscribed functions (Leech and Sharp, 2014; Seeley et 
al., 2007). These large-scale brain networks comprise cortical and subcortical areas 
and their interconnecting structural or functional connections. Some brain areas 
perform important integrative roles in networks (hubs) because they display an 
unusually high degree of intermodular connectivity which is not critical to 
distinctive functions of the brain (van den Heuvel et al., 2013). Findings from a 
human brain structural connectivity study using diffusion imaging and tractography 
suggest that damage to hub regions has a larger disruptive effect on network 
communication than damage to non-hub regions of a network (van den Heuvel et 
al., 2013). This finding may explain why damage of two cingulate structural 
networks is associated with important dysfunctions on the level of cognition and 
vigilance. 
 
Strengths and limitations  
The strength of this study lies in detecting grey matter changes with a novel 
network-based technique in a large group of clinically well characterized PD 
patients with simultaneous acquired MR images. Limitations of our study are 
related to the cross-sectional design. A longitudinal design is preferable to assess 
the relationship between network integrity and disease progression. Further, our 
population is characterized by patients with mild to moderate disease severity, 
limiting the generalizability of the results to the PD population at large. 
Nonetheless, it is notable that even in these patients SCN analysis was able to 
detect distinct regions of grey matter atrophy, which were related to severity of 
predominantly non-dopaminergic symptoms in two domains. Patients were tested 
while on dopaminergic medication. In addition, the depression scale (the Hospital 
Anxiety and Depression Scale) (Zigmond and Snaith, 1983), from which items for 
the depression domain of the SENS-PD were taken, inquires after symptoms in the 
last week and was completed in the week before the MRI was made, when patients 
took their regular medication. We cannot rule out that this may have resulted in a 
decrease of symptom scores that show some sensitivity to dopaminergic influences 
and possibly have attenuated the examined associations. This likely played a less 
prominent role with regard to the total SENS-PD scale, which includes symptoms 
that mainly do not improve with dopaminergic medication, although there are 
potentially some positive effects on depression (Chaudhuri and Schapira, 2009). 
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Conclusion 
In conclusion, SCN analysis in mild to moderate PD revealed a loss of integrity of 
the anterior and posterior cingulate SCN, which in turn was explained by grey 
matter loss in specific brain regions within the networks. The identified structural 
changes were associated with cognitive impairment and excessive daytime 
sleepiness, suggesting that components of both cingulate SCNs may operate as 
important interfaces between different functional networks involved in cognition 
and alertness. 
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ABSTRACT 
 
Introduction: Dementia with Lewy bodies (DLB) and Parkinson’s disease (PD) are 
considered subtypes of the alpha-synucleinopathy continuum that show similar and 
dissimilar clinical and morphological features. To further our understanding of brain 
abnormalities that might differentiate both disorders more clearly, we performed 
quantitative magnetic resonance (MR) imaging of the subcortical and cortical grey 
matter.  
 
Methods: Three-dimensional T1 weighted 3 tesla MR images of 14 DLB and 62 
age- and gender-matched PD patients were examined to study cortical and 
subcortical grey matter structure. We used volumetric measurements to study total 
grey matter, and volumes of the pallidum, amygdala, putamen, caudate nucleus, 
thalamus and hippocampus. Whole-brain and structural network-based methods 
were used to identify local differences in grey matter and vertex-based shape 
analysis was used to assess focal hippocampal changes.  
 
Results: Volumetric, whole-brain and network-based analyses showed reduced 
hippocampal (p = 0.008) and right parahippocampal region volumes (p = 0.030) in 
DLB compared to PD patients. Shape analysis showed atrophy in the head and 
body of the right (p = 0.040) and in the head of the left (p = 0.030) hippocampus 
of DLB patients. 
 
Conclusion: DLB patients showed atrophy of the hippocampus and 
parahippocampal gyrus compared to PD patients with a differential involvement of 
the head and body of the hippocampus. Further studies should examine if these 
group-based findings can be used to differentiate both disorders on an individual 
level.    
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INTRODUCTION 
Dementia with Lewy bodies (DLB) and Parkinson’s disease (PD) are both conditions 
characterized by the presence of alpha-synuclein in Lewy bodies and Lewy neurites 
(Jellinger, 2009). Clinical features of patients with DLB and PD overlap, such as 
symptoms of parkinsonism, psychiatric/behavioral symptoms, autonomic 
dysfunction and cognitive impairment (McKeith et al., 2017; Postuma et al., 2015). 
However, the timing of symptoms, progression rate, and severity are 
different, and DLB patients show a decreased efficacy and tolerance of medication. 
DLB is diagnosed when dementia occurs before or concurrently with parkinsonism 
(McKeith et al., 2017). On the contrary, dementia occurring in the presence of well-
established PD, is classified as PD with dementia (PDD) (McKeith et al., 2017). It is 
debated whether this distinction is valid (Postuma et al., 2016, 2015), as it is 
increasingly recognized that cognitive impairment and dementia are common in all 
stages of PD, and it is the only common manifestation of both disorders that is 
being regarded in this manner (Chahine et al., 2016; Postuma et al., 2016).  
At present, a clear distinction, if at all possible, between both disorders is 
also difficult, because the exact pathogenic mechanisms underlying the clinical 
heterogeneity are unknown. Previous structural MRI studies have shown grey 
matter atrophy in DLB and PD patients compared to control subjects (Mak et al., 
2014; Pan et al., 2012; Sterling et al., 2016; Watson and Colloby, 2016). Notably, 
there is evidence that there may be structural brain differences in grey matter 
between DLB and PD patient as well. However, until now, most studies focused on 
differences between DLB patients and healthy control subjects, patients with 
Alzheimer’s disease and patients with PDD (Mak et al., 2014). One study compared 
total grey matter of DLB and PD patients and showed more pronounced atrophy 
in DLB (Borroni et al., 2015), although DLB and PD groups were not matched for 
age or gender in this study, which may have influenced the results. Reduced 
cortical and subcortical volumes have further been found in DLB compared to PD 
patients, using region of interest approaches (Gazzina et al., 2016; Kenny et al., 
2008; Tam et al., 2005).  
In the present study, we therefore evaluated if whole-brain and network-
based magnetic resonance imaging (MRI) approaches to measure total and 
subcortical grey matter volume(s), may contribute in differentiating both disorders 
more clearly. Finally, vertex-based shape analysis was used to assess focal changes 
of subcortical structures. 
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METHODS 
Study design and participants 
 
 
Figure 1. Flowchart of inclusion for DLB patients. 
 
The present cross-sectional study is part of the Profiling Parkinson’s disease 
(PROPARK) study. Patients were recruited from the outpatient clinic for Movement 
Disorders of the Department of Neurology of the Leiden University Medical Center 
(LUMC, Leiden, the Netherlands) and nearby university and regional hospitals 
between January 2013 and January 2016. Evaluations occurred at the LUMC. 
Fourteen DLB patients were included (figure 1). Sixty-two PD patients were 
selected from the PROPARK cohort, matched at group level for age and gender to 
the DLB patients. All PD patients fulfilled the United Kingdom Parkinson’s Disease 
Society Brain Bank criteria for idiopathic Parkinson’s disease (Gibb and Lees, 1988) 
and  all DLB patients fulfilled the McKeith diagnostic criteria for probable DLB 
(McKeith et al., 2005). Patients were diagnosed with DLB or PD by a movement 
disorder specialist. Exclusion criteria were: previous or other disorders of the 
central nervous system, peripheral nerve disorders influencing motor and/or 
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autonomic functioning, and psychiatric comorbidity not related to PD. All 
participants or his/her closest relative provided written informed consent 
according to the Declaration of Helsinki. Ethical approval was given by the Medical 
Ethics Committee of the LUMC. 
 
Clinical assessments 
All patients underwent standardized assessments, including an evaluation of 
demographic and clinical characteristics. Participants were tested while on 
dopaminergic medication (except for nine drug-naïve PD and eight drug-naïve DLB 
patients). The Movement Disorder Society unified Parkinson's disease rating scale 
(MDS-UPDRS) motor scale (part III) was used to quantify the severity of motor 
signs (Goetz et al., 2008). Additionally, the severity of non-dopaminergic 
symptoms in Parkinson’s disease (SENS-PD) scale was used (van der Heeden et al., 
2016), which is a composite score comprising three items with four response 
options (0-3) from each of the following domains: postural instability and gait 
difficulty, psychotic symptoms, excessive daytime sleepiness, autonomic dys-
function, cognitive impairment and depressive symptoms (total range: 0-54). These 
six domains represent a coherent complex of symptoms that largely do not 
improve with dopaminergic medication, that is already present in the early disease 
stages and increases in severity when the disease advances. Higher scores on both 
scales reflect more severe impairment. The mini-mental state examination (MMSE) 
(Folstein et al., 1975) and scales for outcomes in Parkinson's disease - cognition 
(SCOPA-COG, cognitive functioning, range 0-43) were used to assess cognitive 
performance. The SCOPA-COG is a valid and reliable instrument examining the 
following domains: memory, attention, executive functioning and visuospatial 
functioning (Marinus et al., 2003); lower scores reflect more severe impairment. 
Hallucinations were quantified using the hallucination item of the SCOPA -
psychiatric complications (PC, range 0 -3) scale (Visser et al., 2007). A levodopa 
dose equivalent (LDE) of daily levodopa (LDE-Dopa), dopamine agonists (LDE-DA), 
as well as a total LDE was calculated according to the formula developed by 
Tomlinson et al. (Tomlinson et al., 2010). 
 
MRI analyses 
Three-dimensional T1-weighted images were acquired on a 3 Tesla MRI scanner 
(Philips Achieva, Best, the Netherlands) with the following parameters: repetition 
time = 9.8 ms, echo time = 4.6 ms, flip angle = 8°, field of view 220 x 174 x 156 
mm, 130 slices with a slice thickness of 1.2 mm with no gap between slices, 
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resulting in a voxel size of 1.15 mm × 1.15 mm × 1.20 mm. All MRI scans were 
visually checked to ensure that no major artifacts or abnormalities were present in 
the data. Analyses were done using the software provided by FMRIB's software 
library (FSL, version 5.0.8, Oxford, United Kingdom) (Smith et al., 2004). Brain 
structures were identified using the Harvard-Oxford atlas integrated in FSL. 
 
Volumetric measurements 
Grey matter volume was estimated with structural image evaluation, using 
normalization, of atrophy cross-sectional (SIENAX) (Smith et al., 2002), starting by 
extracting brain and skull images from the T1-weighted images. The brain image 
is then affine-registered to Montreal Neurological Institute (MNI) standard space, 
using the skull image to determine the registration scaling. This is primarily done 
in order to obtain the volumetric scaling factor, to be used as a normalization for 
head size. Next, tissue-type segmentation with partial volume estimation is carried 
out in order to calculate total volume of brain tissue and separate estimates of 
volumes of grey and white matter. FMRIB’s integrated registration and 
segmentation tool (FIRST) (Patenaude et al., 2011) was used to determine volumes 
of the hippocampus, pallidum, amygdala, putamen, caudate nucleus and thalamus 
in cm3. FIRST starts by registering each brain image to MNI standard space and fits 
models for the different structures (meshes) to the images. Boundary correction is 
applied for the volumetric output.  
 
Voxel-based morphometry 
VBM was used to investigate voxel-wise differences in grey matter volume between 
DLB and PD patients (Douaud et al., 2007; Good et al., 2001; Smith et al., 2004). 
Structural images were brain-extracted and grey matter-segmented before being 
registered to the MNI standard space using non-linear registration. The resulting 
images were averaged and flipped along the x-axis to create a left-right symmetric, 
study-specific grey matter template with the same number of DLB and PD subjects, 
in order to create an unbiased template. All native grey matter images were non-
linearly registered to this study-specific template and modulated to correct for 
local expansion (or contraction) due to the non-linear component of the spatial 
transformation. The modulated grey matter images were then smoothed with an 
isotropic Gaussian kernel with a sigma of 3 mm and concatenated into a four-
dimensional data set, which was also used for further network analyses. A voxel-
wise general linear model was applied to the four-dimensional data set, using 
permutation-based non-parametric testing (Winkler et al., 2014), with 5000 
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permutations, correcting for multiple comparisons across space. The statistical 
threshold was set at p < 0.05, familywise error corrected, using the threshold-free 
cluster enhancement (TFCE) technique (Smith and Nichols, 2009). A grey matter 
mask was applied in the statistical analysis and age and gender were used as 
covariates in the model.  
 
Structural covariance networks 
Computational network-based analyses are increasingly important in uncovering 
patterns of brain atrophy, which are not readily apparent by regional structural 
analysis. It is suggested that anatomical structures that are spatially distributed but 
functionally linked, co-vary in grey matter density within individuals across a 
population. These structural covariance networks (SCNs) can be affected by factors 
like age and disease. We used nine bilateral standardized SCNs, for detailed 
information see Hafkemeijer et al. (2014). The networks were derived using an 
independent component analysis, a statistical technique that is also commonly 
used to study functional network integrity. It defines spatial component maps of 
maximal statistical independence. The four-dimensional data set of grey matter 
images derived from our participants was used in a spatial regression against the 
standard SCN probability maps, using a general linear model approach integrated 
in FSL to calculate individual SCN integrity scores. The integrity score is the beta 
coefficient of the regression analysis, reflecting the strength of the individual 
expression in each network. High scores indicate strong individual network 
expression.  
 
Vertex-based shape analysis 
We subsequently analyzed the hippocampal shape differences between DLB and 
PD patients on a per-vertex basis using hippocampal output from FIRST 
(Patenaude et al., 2011). Vertex locations from each subject (at a corresponding 
anatomical point) are projected on a surface constructed from the average shapes 
of all participants. The projections are scalar values that represent the signed, 
perpendicular distance from the average surface, where a positive value is outside 
the surface and a negative value is inside. The projection values were stored in a 
four-dimensional data set, which was used to calculate significant differences in 
shape between the groups. A general linear model was used with an F-test, cluster-
based thresholding corrected for multiple comparisons (Patenaude et al., 2011). 
Age and gender were used as covariates in the statistical model.  
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Statistical analyses in SPSS 
Demographic characteristics were compared using an independent-sample t-test 
(age) and a chi-square test (gender, number of drug-naïve patients for 
dopaminergic medication). Differences in normalized total grey matter volume 
between DLB and PD patients were analyzed with a univariate analysis of variance, 
adjusted for age and gender. Subcortical structure volume differences were 
studied using a univariate analysis of variance, adjusted for age, gender and 
unnormalized total brain volume. Differences in gray matter network scores were 
studied using a univariate analysis of variance, adjusted for age and gender. Within 
DLB patients, we investigated correlations between hippocampal volumes, SENS-
PD and cognitive performance (SCOPA-COG and MMSE scores) and hallucinations 
using Spearman’s rank correlation coefficient. SPSS version 23.0 was used for all 
statistical analyses (IBM SPSS Statistics for Mac, Version 23.0. Armonk, NY: IBM 
Corp.). 
 
RESULTS 
 
Table 1. Main characteristics of participants 
 DLB patients PD patients  
N 14 62 P-value 
Men/women 11/3 44/18 0.745 
Age, years 73.1 (6.0) 71.9 (4.1) 0.597 
Disease duration, years 5.5 (3.4) 8.7 (4.2) 0.011⁎ 
MDS-UPDRS motor score (0-132) 36.5 (19.5) 39.2 (16.7) 0.608 
SENS-PD (0-54)a 24.5 (8.0) 16.2 (5.9) <0.001⁎ 
MMSEb 20.5 (6.0) 28.3 (1.7) <0.001⁎ 
SCOPA-COG (0-43)c 17.1 (5.9) 24.9 (4.1) <0.001⁎ 
SCOPA PC hallucination item (0-3)d 0 (2)^ 0 (0) <0.019⁎ 
Total LDE, mg/daye 389.7 (283.2) 935.7 (513.6) 0.014⁎ 
Drug-naïve patients 8 9 0.001⁎ 
Grey matter volume, normalized 665.3 (32.7) 680.7 (40.7) 0.335 
Values are means (standard deviation) for continuous variables, numbers for gender and median 
(interquartile range) for hallucinations. For all measurement instruments, the score range is 
presented in parentheses. MDS-UPDRS: Movement Disorder Society-unified Parkinson’s disease 
rating scale; SENS-PD: severity of non-dopaminergic symptoms in Parkinson’s disease; MMSE: 
minimal mental state examination; SCOPA-COG: SCOPA cognition; PC: psychiatric complications; 
LDE: Levodopa dosage equivalent; n/a: not applicable.  
^ range: 0–3. DLB/PD: a N = 11/58, b N = 14/60, c N = 12/57, d N = 13/62 e N = 6/51, ⁎ p < 0.05. 
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There were no significant differences in gender, age and motor symptom severity 
(MDS-UPDRS III score) between the groups (table 1). The mean disease duration 
was 3 years shorter in DLB compared to PD patients. DLB patients had a higher 
predominantly non-motor symptoms burden (SENS-PD score: 8 points difference). 
Both groups had cognitive deficits, but DLB patients were more cognitively 
impaired than PD patients (SCOPA-COG: 8 points difference, range 0-43 and 
MMSE score: 8 points difference, range 0-30). DLB patients had more (severe) 
hallucinations than PD patients, as the latter had no or only mild hallucinations with 
complete insight. Six DLB patients used dopaminergic medication, these patients 
used on average 546 mg/day less dopaminergic medication than PD patients. No 
differences in normalized total grey matter volume were found. 
 
Voxel-based morphometry 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. 2A: Brain areas showing reduced (red, red arrows) grey matter volume in DLB 
compared to PD patients, overlaid on the MNI standard cerebral image with accompanying 
coordinates. Results with a threshold-free cluster enhancement (TFCE) familywise error 
corrected p-value < 0.05 are shown. 2B: Grey matter structural covariance posterior 
cingulate cortex network (red), overlaid on the most informative slices of the MNI standard 
cerebral image with accompanying coordinates. Red arrows indicate the parahippocampal 
gyrus and hippocampus. 
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Whole brain voxel-wise differences in grey matter volume are shown in figure 2A. 
DLB patients showed reduced grey matter compared to PD patients in the right 
hippocampus and right parahippocampal regions (figure 2A, red areas, p = 0.030 
most significant voxel). 
 
Volumetric measurements 
Mean total hippocampal volume was 0.7 cm3 lower in DLB compared to PD 
patients (table 2). Volume estimates were also performed for the left and right 
hippocampus separately and showed lower hippocampal volumes in DLB 
compared to PD patients in both the right (p = 0.009, mean difference 0.4 cm3) 
and left (p = 0.026, mean difference 0.3 cm3) hemisphere. In the DLB group, 
associations between hippocampal volume and cognitive performance were tested 
and showed a correlation coefficient of 0.572 (MMSE score; p = 0.033; right 
hippocampus: rs = 0.619, p = 0.018; left hippocampus: rs = 0.384, p = 0.176) and 
0.371 (SCOPA-COG score; p = 0.235; right hippocampus: rs = 0.308, p = 0.330; 
left hippocampus: rs = 0.228, p = 0.477). For hippocampal volume and 
predominantly non-motor symptom severity (SENS-PD score) Spearman’s rho was 
0.055 (p = 0.873; right hippocampus: rs = 0.023, p = 0.947; left hippocampus: rs = 
0.077, p = 0.821). The correlation coefficient for hippocampal volume and 
hallucinations (hallucination item SCOPA-PC) in the DLB group was -0.477                
(p = 0.100; right hippocampus: rs = -0.547, p = 0.053; left hippocampus: rs = -0.358, 
p = 0.229). 
 
Table 2. Volumetric measurements 
 DLB patients PD patients  
N 14 62 P-value 
Hippocampus 6.4 (0.3) 7.1 (0.1) 0.008⁎ 
Pallidum 3.5 (0.2) 3.6 (0.1) 0.458 
Amygdala 2.4 (0.1) 2.3 (0.1) 0.444 
Putamen 8.5 (0.3) 8.8 (0.1) 0.291 
Caudate nucleus 6.7 (0.2) 6.6 (0.1) 0.666 
Thalamus 13.9 (0.3) 14.2 (0.1) 0.284 
Values are estimated marginal means in cm3 (standard error), reported as the combined volume of 
right and left regions, adjusted for age and gender and unnormalized total brain volume. ⁎p < 0.05. 
 
Vertex-based shape analysis 
Based on the findings of the volumetric measurements and VBM we performed a 
vertex-based shape analysis to explore potential shape differences of the 
hippocampus between DLB and PD patients. Atrophy was found in the head and 
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body of the right (p = 0.040; figure 3) and in the head of the left hippocampus       
(p = 0.030; figure 3) of DLB compared to PD patients. 
 
 
Figure 3. Atrophy (red) of the hippocampus (blue) in DLB compared to PD patients. Results 
with familywise error corrected p-value <0.05 are shown. 
 
Structural covariance networks 
 
Table 3. Structural covariance networks 
 DLB patients PD patients  
N 14 62 P-value 
A  Thalamus network 0.003 (0.002) 0.001 (0.001) 0.472 
B  Lateral occipital cortex network 0.018 (0.002) 0.019 (0.001) 0.471 
C  Posterior cingulate cortex network 0.044 (0.002) 0.050 (0.001) 0.009⁎ 
D  Anterior cingulate cortex network 0.026 (0.002) 0.028 (0.001) 0.572 
E  Temporal pole network 0.005 (0.002) 0.006 (0.001) 0.391 
F  Putamen network 0.019 (0.002) 0.019 (0.001) 0.825 
G  Cerebellum network 0.031 (0.002) 0.030 (0.001) 0.922 
H  Cerebellum network 0.016 (0.002) 0.016 (0.001) 0.959 
I  Cerebellum network 0.006 (0.002) 0.008 (0.001) 0.134 
Structural covariance networks are named based on the predominant brain region in the 
network. Values are estimated marginal means (standard error), adjusted for age and gender.  
⁎ p < 0.05. 
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Integrity scores of nine structural covariance grey matter networks are shown in 
table 3. In DLB patients, the integrity of the anatomical posterior cingulate cortex 
network (network C: comprising regions of the parahippocampal gyrus and 
hippocampus; figure 2B) was significantly lower than in PD patients (p = 0.009). No 
significant differences were found in the other eight structural covariance networks 
between DLB and PD.   
 
DISCUSSION 
The results of this study using different MRI approaches to evaluate grey matter 
show a consistent (para)hippocampal volume loss in DLB compared to PD patients. 
Vertex-based shape analysis further showed atrophy in the head and body of the 
right and head of the left hippocampus in DLB compared to PD patients. Except 
for (para)hippocampal atrophy in DLB patients, no other structural differences in 
grey matter between DLB and PD patients were found.  
The findings in this study are in line with the results of earlier studies 
(Gazzina et al., 2016; Kenny et al., 2008; Tam et al., 2005), although these studies 
applied region of interest approaches to investigate differences between DLB and 
PD. Gazzina et al. and Borroni et al. further reported lower thalamus, caudate 
nucleus and middle occipital gyrus volume in DLB compared to PD patients 
(Borroni et al., 2015; Gazzina et al., 2016). In both studies, the DLB group was older 
(Gazzina et al: DLB 74.4 and PD 69.4 year; Borroni et al.: DLB 74.2 and PD 66.3 
year), consisted of more female subjects (Gazzina et al: DLB 43.8% and PD 18.8% 
female; Borroni et al.: DLB 46.2% and PD 9.1% female) and had higher MDS-
UPDRS motor scores than the PD group (Gazzina et al: DLB 20.1 and PD 12.7; 
Borroni et al.: DLB 20.1 and PD 10.7) (Borroni et al., 2015; Gazzina et al., 2016). 
These differences in age, gender and motor symptom severity likely contributed 
to the more extensive reductions in grey matter in DLB patients as compared to 
the findings in our study. 
Our study shows regional atrophy in the head and body of the right and 
head of the left hippocampus in DLB compared to PD patients. To our knowledge, 
this is the first study in which vertex-based shape differences between DLB and PD 
patients are investigated. Neuropathological studies indicate a relative 
preservation of the CA1 and subiculum in DLB patients versus healthy control 
subjects, Alzheimer’s disease, and PD patients (Antony J. Harding et al., 2002; 
Lippa et al., 1994). MRI studies investigating hippocampal subfields in Alzheimer’s 
disease and DLB patients report a relative preservation of the CA1 in DLB patients 
as well (Delli Pizzi et al., 2016; Mak et al., 2016). Collectively, the findings of all 
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studies indicate that further exploration of regional atrophy of the hippocampus 
and its subfields in differentiating DLB from PD may be worthwhile.    
We found that hippocampal volume correlated with cognitive performance 
(MMSE score) in DLB patients, although 14 is a small sample size to perform a 
correlation analysis. Nevertheless, the findings are in line with previous studies 
reporting that atrophy of the hippocampus and parahippocampal gyrus in DLB 
patients is correlated with cognitive decline (Tagawa et al., 2015; Yavuz et al., 
2007). Brain amyloid beta deposition, including deposition in the hippocampus, is 
more marked in DLB (Gomperts, 2014). Although the development of cognitive 
impairment and dementia seems multifactorial, brain deposition of amyloid beta is 
proposed to contribute to cognitive impairment in DLB and PD (Gomperts, 2014). 
Moreover, current data suggest that concomitant amyloid beta and alpha-
synuclein pathology may act synergistically to contribute to cognitive impairment 
(Gomperts, 2014). 
Our findings in DLB patients were most pronounced in the right 
hemisphere, which is in accordance with earlier studies showing prominent 
structural and functional alterations in the right hemisphere of DLB patients (Delli 
Pizzi et al., 2016; Sabattoli et al., 2008). There are indications that a predominance 
of the right hemisphere for visuospatial processing plays a role in visual 
hallucinations (Delli Pizzi et al., 2016; Jonas et al., 2014; Sanchez-Castaneda et al., 
2009). DLB patients in this study had more (severe) hallucinations than PD patients 
and although we do not have data on the different types of hallucinations, visual 
hallucinations generally predominate in DLB and PD (Eversfield and Orton, 2018). 
Visual hallucinations are a core feature of DLB (McKeith et al., 2017) and, compared 
to PD, their prevalence is much higher (Antony J. Harding et al., 2002). In particular 
the atrophy that we found of the right parahippocampal gyrus in this study could 
be related to visual hallucinations in DLB patients (A. J. Harding et al., 2002; Heitz 
et al., 2015). Heitz et al. found a correlation between perfusion of the right 
parahippocampal gyrus and the severity of visual hallucinations in DLB patients 
(Heitz et al., 2015), while Harding et al. showed that higher Lewy body densities in 
the parahippocampal gyrus were associated with visual hallucinations in DLB 
patients (A. J. Harding et al., 2002). Another study compared DLB with AD patients 
and also found parahippocampal atrophy in DLB patients (Delli Pizzi et al., 2016), 
supporting the hypothesis that the parahippocampal gyrus plays an important role 
in visual hallucinations in DLB patients.  
We used well-established, reproducible, data-driven methods to 
investigate grey matter in DLB and PD. We found consistent (para)hippocampal 
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volume loss in DLB compared to PD patients, despite the relatively small number 
of DLB patients. Nevertheless, the results should be verified in a larger number of 
subjects. The mean disease duration of the DLB group was shorter than of the PD 
group in this study and our results may have been more pronounced with similar 
mean disease durations in both groups. Both groups had a comparable motor 
symptom severity, but DLB patients had higher predominantly non-dopaminergic 
symptoms scores and a worse cognitive performance than PD patients. Especially 
cognitive performance may have contributed to the hippocampal atrophy in DLB 
patients that we found. An additional group of PDD patients may provide 
additional inside into the relationship between cognition and our findings. 
However, it should be considered that PDD generally develops quite late in the 
disease course, and a large difference in disease duration between groups might 
lead to difficulties in attributing potential group differences to either differences in 
disease duration or disease type. It should further be noted that our study was set 
up to examine structural grey matter differences between DLB and PD patients, 
and the absence of a group of healthy control subjects did not allow for the 
detection of regions that are affected by atrophy in both PD and DLB patients. 
However, previous studies have shown grey matter atrophy in PD and DLB patients 
as compared to healthy control subjects (Mak et al., 2014; Pan et al., 2012; Sterling 
et al., 2016; Watson and Colloby, 2016).  
  To summarize, our data unequivocally show atrophy of the hippocampus 
and parahippocampal gyrus in DLB patients as compared with PD patients. Vertex-
based shape analysis confirmed atrophy of the hippocampus in DLB, localized in 
the head and body. Moreover, integrity of the anatomical network that comprised 
(para)hippocampal regions, was significantly lower in DLB. These findings indicate 
that regional hippocampal differences between DLB and PD may be important in 
the distinction between the two disorders. 
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ABSTRACT 
 
Introduction: As age and Parkinson’s disease (PD) both play a role in the 
degeneration of brain white matter, we aimed to investigate a possible interaction 
effect of age and disease presence on white matter integrity in patients with PD.  
 
Methods: We studied white matter hyperintensity (WMH) volume, global fractional 
anisotropy, mean diffusivity and mean magnetization transfer ratio of normal 
appearing white matter in 163 patients with PD and 218 age and gender-matched 
healthy control subjects. We investigated the relationship between age and these 
parameters in both groups, and interaction between age and disease presence.  
 
Results: Patients with PD had higher total, periventricular and anterior WMH 
volumes as compared with control subjects. Age-related WMHs were found in both 
groups in periventricular and posterior, but not in anterior brain regions. 
Visuospatial functioning was related to total and postural instability and gait 
difficulty were related to periventricular WMH volume in patients with PD. Global 
microstructural integrity of the normal appearing white matter did not differ 
between patients and control subjects. In both groups, the global microstructural 
integrity decreased with advancing age. No age-by-disease interaction effects 
were found. 
 
Conclusion: Patients with PD had a higher load of WMHs with a preferential 
periventricular and anterior distribution as compared with healthy control subjects. 
The age-related decline of white matter integrity was similar for both groups. 
Global microstructural integrity of the normal appearing white matter was relatively 
normal in patients with PD, suggesting that PD-specific changes do not exceed 
normal age-associated change in white matter without lesions. 
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INTRODUCTION 
The clinical spectrum of motor and non-motor symptoms in Parkinson’s disease 
(PD) is linked to a progressive formation of alpha-synuclein aggregates, 
predominantly located in presynaptic terminals (Jellinger, 2012; Kramer and 
Schulz-Schaeffer, 2007). The primary determinant of neurodegeneration in patient 
with PD may be alpha-synuclein aggregate related synaptic and axonal dysfunction 
(Jellinger, 2012; O’Malley, 2010; Tagliaferro et al., 2015). White matter changes 
represent degeneration of axons and myelin damage, and white matter 
degeneration is increasingly recognized in patients with PD (Chiang et al., 2017; 
Chondrogiorgi et al., 2016; Sterling et al., 2017). 
Magnetic resonance imaging (MRI) studies have found white matter 
changes in patients with PD (Atkinson-Clement et al., 2017; Bohnen and Albin, 
2011), but such changes may occur as a consequence of aging (Galluzzi et al., 2008; 
Lockhart and DeCarli, 2014). With advancing age, the prevalence of white matter 
hyperintensities (WMHs) increases (Galluzzi et al., 2008; Grueter and Schulz, 2012), 
and white matter microstructural integrity surrounding these lesions (the so called 
normal appearing white matter; NAWM), declines (Lockhart and DeCarli, 2014; 
Vernooij et al., 2008). These findings thus raise the question to what extent white 
matter changes in PD are related to aging.   
We hypothesized that the white matter integrity decline is significantly 
greater in patients with PD than seen in healthy aging subjects and that there may 
be an age-by-PD interaction effect on white matter integrity. To this end, we 
compared macrostructural integrity of global white matter and the microstructural 
integrity of the surrounding NAWM between patients with PD and control subjects. 
The relationship between age and white matter integrity was estimated in both 
groups, and the interaction between age and disease presence was examined to 
investigate if age-related white matter changes are different in PD compared with 
healthy aging. We further explored associations of clinical variables, other than 
age, with white matter integrity.  
 
METHODS 
Participants 
We included 163 patients with PD in this cross-sectional MRI study, which is a 
project of the Profiling Parkinson’s disease (PROPARK) research group. Patients 
were recruited between 2013 and 2016 from the outpatient clinic for Movement 
Disorders of the Department of Neurology of the LUMC (Leiden University Medical 
Center; Leiden, the Netherlands) and nearby university and regional hospitals. All 
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patients with PD fulfilled the United Kingdom Parkinson’s Disease Society Brain 
Bank criteria for idiopathic PD (Gibb and Lees, 1988). Exclusion criteria were 
previous or other disorders of the central nervous system, peripheral nerve 
disorders influencing motor and/or autonomic functioning, and psychiatric 
comorbidity not related to PD. Patients were matched at group level for age and 
gender with 218 healthy control subjects from the Leiden Longevity study (LLS), a 
study set up to identify genetic and phenotypic determinants of longevity in 
healthy long-living families (Altmann-Schneider et al., 2013). Written consent was 
obtained from all participants. The Medical Ethics Committee of the LUMC 
approved the PROPARK study and LLS. 
 
Clinical assessments 
Standardized assessments were performed in all patients, including an evaluation 
of demographic and clinical characteristics. Patients were tested while on 
dopaminergic medication, except for 24 “de novo” patients, defined as 
dopaminergic drug-naïve patients with a disease duration shorter than 5 years, and 
2 other drug-naïve patients with a disease duration longer than 5 years. Motor 
symptoms were quantified with the Movement Disorder Society unified Parkinson’s 
disease rating scale (MDS-UPDRS) motor scale (part III) (Goetz et al., 2008). Missing 
values were imputed with the average score of the remaining questions, allowing 
a maximum of 7 missing values (Goetz et al., 2015). We calculated motor domain 
scores as well: Bradykinesia (items 3.4, 3.5, 3.6, 3.7, 3.14); rigidity (item 3.3); tremor: 
items 3.16, 3.17, 3.18); postural instability and gait difficulty (items 3.9, 3.10, 3.11, 
3.12, 3.13). We used the severity of non-dopaminergic symptoms in Parkinson’s 
disease (SENS-PD) scale, representing a coherent complex of symptoms that 
largely do not improve with dopaminergic medication, that is already present in 
the early disease stages, and increases in severity when the disease advances (van 
der Heeden et al., 2016). It comprises three items with four response options (0-3) 
from each of the following six domains: postural instability and gait difficulty, 
psychotic symptoms, excessive daytime sleepiness, autonomic dysfunction, 
cognitive impairment and depressive symptoms (total range: 0-54) (van der 
Heeden et al., 2016). Higher scores on both scales reflect more severe impairment. 
Cognitive performance was assessed with the scales for outcomes in Parkinson's 
disease - cognition (SCOPA-COG; cognitive functioning; range 0-43), which is a 
valid and reliable instrument examining the following domains: memory, 
attention, executive functioning and visuospatial functioning (Marinus et al., 2003); 
lower scores reflect more severe impairment. A levodopa dose equivalent (LDE) 
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was calculated according to the formula developed by Tomlinson et al. (Tomlinson 
et al., 2010). Patients were further asked if they had vascular risk factors: smoking, 
myocardial infarction, diabetes mellitus, hypertension, use of statins, transient 
ischemic attack and stroke, although previous stroke was an exclusion criterion for 
the study.  
 
MRI acquisition and analysis 
Imaging was performed on a 3 Tesla MRI scanner (Philips Achieva, Best, the 
Netherlands). Three-dimensional T1-weighted anatomical images were acquired 
with the following parameters: repetition time (TR)/echo time (TE) = 9.8/4.6 ms, 
flip angle = 8°, field of view (FOV) = 220 × 174 × 156 mm, voxel size = 1.15 × 1.15 
× 1.20 mm. Fluid attenuated inversion recovery (FLAIR) images were acquired with 
TR/TE = 9249/56 ms, flip angle = 90°, FOV = 220 × 220 × 128 mm, voxel size = 
1.96 × 1.96 × 2.00 mm. DTI images were acquired along 32 non-collinear directions 
with a b-value of 1000 s/mm2 and one b = 0 image with TR/TE = 9249/56 ms, flip 
angle = 90°, 32 axial slices, voxel size = 1.96 × 2.00 × 2.00 mm, FOV = 220 × 220 
× 128. MTI parameters were: TR/TE = 100/11 ms, flip angle = 9°, voxel size = 1.00 
× 1.00 × 7.20 mm, FOV = 224 × 180 × 144 mm. Before analysis, all MRI scans were 
visually checked to ensure that no major artifacts or abnormalities were present in 
the data. MR images were analyzed with software provided by FSL (version 5.0.8, 
Oxford, United Kingdom) (Smith et al., 2004). 
 
White matter hyperintensities 
WMH volume was quantified in an automated manner, defined as hyperintense 
regions on FLAIR. The T1-weighted images were brain-extracted (Smith, 2002) and 
FLAIR and T1-weighted images were non-linearly registered to MNI standard 
space (Andersson et al., 2007). White matter was extracted from the FLAIR image 
using an MNI152 white matter mask. A threshold of 2.5 standard deviations above 
the mean of FLAIR intensities for white matter was set to identify which white 
matter voxels were hyperintense. We additionally calculated WMH volumes for 
periventricular and deep white matter (Fazekas et al., 1987). We created a 
periventricular white matter mask by subtracting an MNI ventricle mask from an 
MNI ventricle mask that was dilated using a 4 × 4 × 4 kernel. An anterior deep 
white matter mask was created using the anterior part of the previously used MNI 
white matter mask (most frontal part of the corpus callosum, MNI coordinate Y = 
33), of which the periventricular white matter mask was subtracted. A posterior 
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deep white matter mask was created similarly (most posterior part of the corpus 
callosum, MNI coordinate Y = -44). 
 
Diffusion tensor imaging 
The preprocessing of the DTI data consisted of brain extraction (Smith, 2002), 
motion and eddy current correction (Andersson and Sotiropoulos, 2016). The 
corrected DTI was subsequently used to create individual fractional anisotropy (FA) 
and mean diffusivity (MD) images using a weighted least squares fitting procedure. 
All subjects’ FA and MD data were aligned into a common space using nonlinear 
registration (Andersson et al., 2007). The resulting images were used for 
quantification of global mean FA and MD values of each subjects NAWM (i.e. white 
matter without lesions). T1-weighted images were brain-extracted (Smith, 2002) 
and segmented in order to create individual white matter masks (Zhang et al., 
2001), which were linearly registered to MNI space (Jenkinson et al., 2002b). Then, 
WMHs of each subject were dilated using a 3 × 3 × 1 kernel and subtracted from 
the individual white matter mask in order to create a NAWM mask. Finally, 
individual mean FA and MD values were calculated using the normal appearing 
white matter mask.  
 Voxel-wise statistical analyses of the FA and MD data were carried out with 
tract-based spatial statistics (TBSS), using default settings (Smith et al., 2006). TBSS 
projects all subjects' aligned FA (or MD) data onto a mean white matter tract 
skeleton. The resulting four-dimensional data was used for further statistical 
analysis. 
 
Magnetization transfer imaging 
The MT images and the previously derived individual NAWM (WMHs subtracted 
from white matter) were linearly registered to T1 space (Jenkinson et al., 2002b). 
Global magnetization transfer ratio (MTR) values were calculated per voxel as (M0 
– Ms) / M0 (Ms: saturated image; M0: unsaturated image). MTR histograms were 
generated using the normal appearing white matter mask in order to calculate the 
mean MTR from each histogram, which is the mean of the MTR value of all voxels 
in the histogram.  
 
Statistical analysis 
Differences between patients and control subjects in WMH volumes, global mean 
FA, MD and mean MTR values of NAWM (white matter integrity measurements) 
and age were analyzed with independent-sample T-tests, dichotomous variables 
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using a chi-square test or Fisher exact test. We used linear regression analyses for 
estimating the relationships between age and measurements of white matter 
integrity in patients and control subjects. Total WMH volumes were transformed 
using the logarithm function to meet normality assumptions. We examined the 
interaction between age and disease presence on white matter integrity 
(dependent variable) in a general linear model, with disease presence and age also 
included as independent variables; gender was included in the model as an 
independent variable as well. Within the PD group, we used a linear regression 
analysis to estimate the relationships between clinical variables (independent 
variable; disease duration, MDS-UPDRS motor, SENS-PD and SCOPA-COG score, 
total LDE, presence of vascular risk factors and hypertension) and WMH volumes 
(dependent variable; total, deep anterior and periventricular WMH volume). With 
regard to the sum scores of the MDS-UPDRS motor, SENS-PD and SCOPA-COG 
scale, we first examined associations between sum scores and WMH volume. We 
subsequently examined associations between the domain scores and WMH volume 
if there was a statistically significant association (defined as p < 0.05) with one of 
the MDS-UPDRS motor, SENS-PD, or SCOPA-COG scale sum scores. We added 
age to the statistical model if a relationship was statistically significant after 
Bonferroni correction was applied. Statistics were performed in SPSS (IBM SPSS 
Statistics for Mac, Version 23.0. Armonk, NY: IBM Corp.). 
Voxel-wise statistical analysis of the FA and MD data was carried out using 
a general linear model approach as implemented in FSL, with gender used as 
covariate in the model as we did in the other statistical analyses. The spatial 
relationship between age and FA, and age and MD data was studied in the PD as 
well as in the control group. Permutation-based non-parametric testing was used 
(Winkler et al., 2014), with 5000 permutations, correcting for multiple comparisons 
across space. The statistical threshold was set at p < 0.05, familywise error (FWE) 
corrected, using the threshold-free cluster enhancement (TFCE) technique (Smith 
and Nichols, 2009). 
 
RESULTS 
Demographic characteristics 
There were no statistically significant differences in age and gender between the 
patient and the control group (table 1). Patients with PD had higher WMH volumes 
(p < 0.001) compared with control subjects. The periventricular (p < 0.001) and 
deep anterior (p < 0.001) WMH volumes were larger in PD patients than in control 
subjects. We did not find statistically significant differences in deep posterior WMH 
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volumes, and also white matter microstructure parameters (i.e., FA, MD, MTR) did 
not significantly differ between groups. 
 
Table 1. Main characteristics of participants 
 PD patients Control subjects  
N 163 218 P-value 
Men/women 59/104 (63.8) 137/81 (62.8) 0.915 
Age, years 64.8 (7.2) 65.0 (6.2) 0.462 
Disease duration, years 9.1 (4.9) n/a n/a 
MDS-UPDRS motor score (0-132) 34.3 (15.6) n/a n/a 
SENS-PD (0-54) 13.2 (6.1) n/a n/a 
SCOPA-COG (0-43) 27.5 (11 - 41) n/a n/a 
Total LDE, mg/day 1017.1 (558.7) n/a n/a 
Vascular risk factors 
 Hypertension 
 Use of statins 
 Diabetes mellitus 
 Myocardial infarction 
 Transient ischemic attack 
 Smoking 
 
32 (20.0) 
19 (11.7) 
6 (3.9) 
4 (2.6) 
2 (1.3)  
10 (6.1) 
 
39 (25.0) 
15 (7.8) 
10 (5.0) 
5 (3.2) 
2 (1.3) 
29 (13.4) 
 
0.345 
0.211 
0.616 
0.748 
1.000 
0.006⁎ 
White matter hyperintensity volume, ml 
 Periventricular white matter 
 Anterior deep white matter 
 Posterior deep white matter 
8.8 (7.2) 
3.6 (2.3) 
0.2 (0.2) 
1.6 (1.7) 
4.8 (5.1) 
2.2 (1.7) 
0.03 (0.1) 
1.7 (1.7) 
<0.001⁎ 
<0.001⁎ 
<0.001⁎ 
0.378 
Mean FA normal appearing white matter 0.30 (0.02) 0.29 (0.02) 0.090 
Mean MDa normal appearing white matter 0.92 (0.06) 0.92 (0.05) 0.850 
Mean MTR normal appearing white matter 0.33 (0.02) 0.33 (0.01) 0.858 
Values are means (standard deviation) for continuous variables, except for SCOPA-COG score 
(range), and numbers for gender (% men) and vascular comorbidity (% yes). For all measurement 
instruments, the score range is presented in parentheses. MDS-UPDRS: Movement Disorder Society-
unified Parkinson’s disease rating scale; SENS-PD: severity of non-dopaminergic symptoms in 
Parkinson’s disease; SCOPA-COG: scales for outcomes in Parkinson's disease - cognition; LDE: 
Levodopa dosage equivalent; n/a: not applicable.  
a Absolute mean MD white matter values multiplied by 1000; ⁎ p < 0.05. 
 
Age and white matter hyperintensity volume  
In the PD group and the control group, total WMH volume increased with age (PD 
group: b = .329, p < 0.001; control group: b = .341, p < 0.001; see figure 1a). There 
was no statistically significant interaction of age and disease presence in their 
effects on WMH volume. Periventricular (PD group: b = .364, p < 0.001; control 
group: b = .364, p < 0.001) and deep posterior (PD group: b = .242, p < 0.002; 
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control group: b = .312, p < 0.001) WMH volumes also increased with age, but 
anterior WMH volume did not.  
 
Figure 1. Scatterplot of the 
relation between age and log-
transformed white matter 
hyperintensity (WMH) volume 
(a), normal appearing white 
matter fractional anisotropy (FA; 
b), normal appearing white 
matter mean diffusivity (MD) 
multiplied by 1000 (c) and 
normal appearing white matter 
mean magnetization transfer 
ratio (MTR; d). Abbreviation: PD, 
Parkinson’s disease. 
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We found that in the PD group, visuospatial functioning (SCOPA-COG 
score) was related to total WMH volume (b = -.214, p = 0.006) and postural 
instability and gait difficulty (UPDRS motor score) to periventricular WMH volume 
(b = .257, p = 0.001). Both relationships remained significant after including age in 
the model: visuospatial functioning with total WMH volume: b = -.175, p = 0.020 
(age with total WMH volume: b = .307, p < 0.001) and postural instability and gait 
difficulty with periventricular WMH volume: b = .163, p = 0.037 (age with 
periventricular WMH volume: b = .314, p < 0.001). No other significant 
relationships between clinical variables and WMH volumes emerged.  
 
 
Figure 2. Areas of age-related decline in white matter fractional anisotropy (FA, blue) and 
age-related increase in white matter mean diffusivity (MD, red), overlaid on the MNI 
standard cerebral image with accompanying coordinates. Left: patients with Parkinson’s 
disease. Right: control subjects. 
 
Age and global white matter microstructural integrity 
Age had a statistically significant association with FA (PD group: b = -.380, p < 
0.001; control group: b = -.392, p < 0.001; see figure 1b), MD (PD group: b = .522, 
p < 0.001; control group: b = .528, p < 0.001; see figure 1c) and mean MTR (PD 
group: b = -.470, p < 0.001; control group: b = -.393, p < 0.001; see figure 1d) in 
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both groups. There was no statistically significant interaction effect of age and 
disease presence on FA, MD, or mean MTR.  
We used TBSS to investigate the spatial voxel-wise relationship between 
age and FA and MD values in the PD as well as in the control group (figure 2). This 
shows that the spatial effect of age on FA and MD is distributed throughout the 
entire brain across white matter tracts in both patients with PD and control 
subjects. 
 
DISCUSSION 
As age and PD both play a role in the degeneration of brain white matter, we 
investigated the relationship between age and white matter integrity in patients 
with PD and control subjects. Although patients with PD had a higher load of white 
matter lesions, the influence of age on the decline of white matter integrity was 
similar to healthy control subjects. In both groups, measures of white matter 
integrity were associated with advancing age, which appeared homogeneously 
distributed across white matter tracts. No differences were found in the degree of 
NAWM degeneration.  
The patients with PD in this study had a higher WMH load than expected 
for their age. The excess of WMHs was partly located in periventricular and deep 
frontal white matter of patients with PD. Besides age, visuospatial functioning and 
postural instability and gait difficulty were related to WMH volume in patients with 
PD. Given the similar age-related increase of WMHs in patients with PD and control 
subjects, our findings may suggest that the pathobiology of PD plays a role in the 
development of WMHs. Our findings are in line with those of other studies showing 
more WMHs in patients with PD (Compta et al., 2016; Dunet et al., 2019; Ham et 
al., 2016; Piccini et al., 1995). Nevertheless, other studies did not show differences 
between patients with PD and healthy control subjects (Acharya et al., 2006; Beyer 
et al., 2006; Dalaker et al., 2009; Sartor et al., 2017). Differences in field strength 
(ranging from 0.5 to 3 Tesla), methodology to asses WMHs, and selection of a 
specific subset of patients with PD (i.e., with/without dementia or mild cognitive 
impairment) in these studies likely contributed to the inconsistent findings. 
Importantly, previous MRI studies investigating WMHs in patients with PD used 
visual rating scales, such as the Fazekas grading system and the Scheltens visual 
rating scale, or semiautomated visual approaches that require manual contouring 
of the lesions. Increased field strength can possibly result in a better delineation of 
white matter lesions (Zwanenburg et al., 2010) and the accuracy of visual rating 
systems may depend on the WMH load. Some scales do not discriminate between 
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no abnormalities and few WMHs or moderate and severe quantities of WMHs, or 
suffer from ceiling effects in patients with a more extensive WMH load (Tiehuis et 
al., 2008; Wardlaw et al., 2004). The automated threshold method to measure 
WMH volume used in our study, however, provides objective and quantitative data 
(Tiehuis et al., 2008). 
Previous studies have shown that WMHs independently contribute to 
postural instability and gait difficulty in patients with PD as well (for review, see 
(Bohnen and Albin, 2011)). There are indications that WMHs may have a substantial 
impact especially on axial motor disability (Lee et al., 2009; Moccia et al., 2016). 
There are also indications that WMHs contribute to cognitive impairment in 
patients with PD (Dadar et al., 2018; Veselý and Rektor, 2016). A recent study found 
increased MD in frontal and parietal white matter tracts in newly diagnosed, 
cognitively intact, patients with PD patients as compared with control subjects, 
which was related to cognitive performance tasks (Duncan et al., 2016). These 
findings suggest that white matter may already be affected in the very early stages 
of PD, predicting future cognitive decline (Dadar et al., 2018; Duncan et al., 2016; 
Veselý and Rektor, 2016). However, some studies reported that the correlations 
found between cognitive measures and WMHs disappeared after adjusting for 
strong confounders, such as age (Bohnen and Albin, 2011; Lee and Lee, 2016). 
Indeed, our findings show that postural instability, gait difficulty, and visuospatial 
functioning are related to the total and to periventricular WMH volume in patients 
with PD, but the relationship between visuospatial functioning and WMHs 
weakened after adjustment for the effect of age in our study too. In addition, the 
relationship between age and WMHs appeared stronger than the relationship 
between visuospatial functioning and WMHs. WMHs might exacerbate cognitive 
or motor dysfunction in patients with PD through aggravation of already impaired 
neuronal connectivity (Veselý and Rektor, 2016). Especially periventricular WMHs 
could interfere with cortico-subcortical circuits that are important for gait and 
balance (Blahak et al., 2009; Bohnen and Albin, 2011). It is debatable whether the 
associations that we found are specific for PD, as WMHs are associated with motor 
and cognitive symptoms in otherwise normal elderly individuals as well (Bohnen 
and Albin, 2011). 
WMHs have been linked to vascular disease, including depositions of 
amyloid beta (Pantoni, 2010). A recent study found more severe WMH burden in 
patients with PD with dementia compared with nondemented patients with PD and 
control subjects, which was related to decreased amyloid beta levels in the 
cerebrospinal fluid in the entire PD sample. Because this finding was independent 
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of age, dementia, APOE-4, and vascular risk factors, the authors suggested a 
possible relationship between brain amyloid deposition and the occurrence of 
WMHs in patients with PD (Compta et al., 2016). At this stage, it remains unclear 
whether the relationship between amyloid beta levels in the cerebrospinal fluid and 
WMHs in PD also reflects vascular amyloid beta deposition. Periventricular WMHs 
may further result from chronic hemodynamic insufficiency (hypoperfusion), 
Wallerian degeneration secondary to neocortical neuron loss in neurodegenerative 
diseases (Bohnen and Albin, 2011; Kim et al., 2008; Leys et al., 1991), or low grade 
inflammation (Bohnen and Albin, 2011; Wersching et al., 2010) to which regional 
differences in gene expression may contribute, resulting in a spatial distribution of 
pathogenic pathways (Ritz et al., 2017). 
The microstructural integrity of the white matter in patients with PD 
without WMHs was normal in terms of global FA, MD, and MTR, compared with 
age-matched control subjects. Previous cross-sectional studies have shown that 
DTI and MTR are particularly relevant for subcortical areas (Atkinson-Clement et 
al., 2017; Tambasco et al., 2015), and show conflicting results in cortical white 
matter, which might be explained by the low statistical power due to small sample 
sizes these studies (Atkinson-Clement et al., 2017; Hall et al., 2016; Tambasco et 
al., 2015). A recent meta-analysis, however, suggested that the cognitive status of 
patients with PD is associated with damage in the temporal and cingulate cortices 
(Atkinson-Clement et al., 2017). A major difference between previously conducted 
studies and our study is that these studies generally applied region of interest 
approaches (Cochrane and Ebmeier, 2013; Tessitore et al., 2016), while we used 
global FA and MD measures of white matter, in order to investigate the 
relationship between age and global white matter integrity in patients with PD. 
Two previous longitudinal studies used a whole brain white matter approach as 
well, and observed similar levels of decline in white matter integrity in patients with 
PD and control subjects (Melzer et al., 2015; Rossi et al., 2014). Other studies 
measured FA reductions and increased MD over time in regions of interest 
(including regions of gray matter), such as the substantia nigra and caudal and 
cerebellar white matter (Pozorski et al., 2018; Zhang et al., 2016). Collectively, all 
findings suggest that PD-specific changes do not exceed normal age-associated 
change in cortical white matter tracts. 
The strengths of our study are the large sample patients with PD and 
control subjects in whom we performed structural MRI as well as DTI and MTI to 
investigate the relationship between age and white matter integrity. We further 
used automated techniques for individual quantification of WMH volume, based 
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on thresholding of hyperintense white matter voxels, which have the advantage of 
improved quantitative assessment of WMHs compared with visual grading (Bohnen 
and Albin, 2011). A limitation of our study is the cross-sectional design to assess 
the age-related decline of white matter, as cross-sectional data rely on between-
person comparisons and not model intraindividual change. White matter changes, 
aging, and cardiovascular risk factors are closely related to each other (Debette 
and Markus, 2010; Erten-Lyons et al., 2013; Wardlaw et al., 2013). It could be 
assumed that the control subjects in this study, who were selected from the LLS, 
may have had a more favorable cardiovascular risk profile as compared with the 
patients with PD in this study. However, cardiovascular risk factors did not differ 
between groups, although it should be noted that the assessed cardiovascular risk 
factors may not have been complete (e.g., the use of statins were compared, but 
not the presence of hyperlipidemia). Of note is that there were more missing values 
in the control group than in the patient group, but we consider it unlikely that this 
may have led to additional bias because there is no reason to assume a relationship 
between missingness and the risk profile of the patient. WMH volume may be 
associated with a worse response to dopaminergic medication for postural stability 
and gait difficulty (Arena et al., 2016). We therefore added total LDE score to the 
model, but this did not change our results. The effects of dopaminergic medication 
on white matter microstructure are not really known, except for a study that 
showed that DTI is not affected by acute antiparkinsonian medication (Chung et 
al., 2017). In our study, microstructural integrity of white matter without WMHs did 
not differ between patients with PD and age-matched control subjects, but subtle 
differences between groups may become apparent through the use of a region of 
interest approach (Pozorski et al., 2018; Zhang et al., 2016). In addition, the rate of 
age-related change may vary across multiple white matter regions, although the 
spatial effect of age on FA and MD was uniformly distributed across white matter 
tracts in both groups. 
 
Conclusion 
Patients with PD had a higher load of WMHs with a preferential periventricular and 
anterior distribution as compared with healthy control subjects. Visuospatial 
functioning was related to total and postural instability and gait difficulty were 
related to periventricular WMH volume in patients with PD. The age-related 
decline of white matter integrity was similar for both groups. Global mean FA, MD, 
and MTR of the NAWM were relatively normal in patients with PD, suggesting that 
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PD-specific changes do not exceed normal age-associated change in white matter 
without lesions. 
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ABSTRACT 
 
Introduction: Functional imaging methods, such as resting-state functional 
magnetic resonance imaging, reflect changes in neural connectivity and may help 
to assess the widespread consequences of disease-specific network changes in 
Parkinson’s disease (PD). In this study we used a relatively new graph analysis 
approach in functional imaging: eigenvector centrality mapping. This model-free 
method, applied to all voxels in the brain, identifies prominent regions in the brain 
network hierarchy and detects localized differences between patient populations. 
In other neurological disorders, eigenvector centrality mapping has been linked to 
changes in functional connectivity in certain nodes of brain networks. Here we 
examined changes in functional brain connectivity architecture on a whole brain 
and network level in patients with PD. 
 
Methods: Whole brain resting-state functional architecture was studied with a 
recently introduced graph analysis approach (eigenvector centrality mapping). 
Functional connectivity was further investigated in relation to eight known resting-
state networks. Cross-sectional analyses included group comparison of functional 
connectivity measures of PD patients (n = 107) with control subjects (n = 58) and 
correlations with clinical data, including motor and cognitive impairment and a 
composite measure of predominantly non-dopaminergic symptoms. 
 
Results: Eigenvector centrality mapping revealed that frontoparietal regions were 
more prominent in the whole-brain network function in patients compared to 
control subjects, while frontal and occipital brain areas were less prominent in 
patients. Using standard resting-state networks, we found predominantly 
increased functional connectivity, namely within sensorimotor system and visual 
networks in patients. Regional group differences in functional connectivity of both 
techniques between patients and control subjects partly overlapped for highly 
connected posterior brain regions, in particular in the posterior cingulate cortex 
and precuneus. Clinico-functional imaging relations were not found. 
 
Conclusion: Changes on the level of functional brain connectivity architecture 
might provide a different perspective of pathological consequences of Parkinson’s 
disease. The involvement of specific, highly connected (hub) brain regions may 
influence whole brain functional network architecture in PD. 
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INTRODUCTION 
Parkinson’s disease (PD) is characterized by a broad spectrum of motor and non-
motor symptoms, which are linked to a progressive formation of alpha-synuclein 
(alpha-SynA) aggregates in presynaptic terminals, Lewy neurites and Lewy bodies 
in neurons of the central and peripheral nervous system (Adler and Beach, 2016; 
Jellinger, 2012). Alpha-SynA are not randomly distributed in the brain, but appear 
in select regions, which likely are affected because of shared anatomical and 
functional properties among neurons (McCann et al., 2016; Surmeier et al., 2017). 
Depositions are most distinct in the midbrain, pontine and medullary nuclei and 
limbic structures, but are also found in the neocortex in the more advanced stages 
of the disease (Jellinger, 2012; McCann et al., 2016). Compelling evidence shows 
that alpha-SynA-related synaptic dysfunction antedates nerve cell loss, suggesting 
that altered neuronal connectivity is a key feature in PD (Schulz-Schaeffer, 2015). 
Functional imaging methods, such as resting-state functional magnetic 
resonance imaging (fMRI), reflect changes in neural connectivity and may help to 
assess the widespread consequences of disease-specific network changes in 
neurodegenerative diseases (Pievani et al., 2011). Former fMRI studies indicate 
decreases as well as increases in functional connectivity in PD patients (Baggio et 
al., 2015; Göttlich et al., 2013). Most of these studies focused on functional 
connectivity of (multiple) brain regions or networks of interest, thus precluding 
inferences on a whole-brain level of integrated networks that are spatially 
distributed, but functionally linked.  
A relatively new graph analysis approach in functional imaging concerns 
eigenvector centrality mapping (ECM). ECM identifies prominent regions in the 
brain network hierarchy and detects localized differences between patient 
populations (Wink et al., 2012). Since this model-free method is applied to all 
voxels in the brain it does not require a priori selection of potentially involved 
networks and is not restricted to one area (regions of interest) of the brain. The 
main difference between the method used in our study and other graph analysis 
studies in PD is that our approach counts the neighbors of each vertex, weighted 
by their centralities (Wink et al., 2012). ECM has been linked to changes in 
functional connectivity in certain nodes of brain networks that might contribute to 
depression in patients with PD (Lou et al., 2015). Changes in ECM have also been 
linked to loss in cognition in APOE ε4 carriers (Luo et al., 2017), but also to 
neurodegenerative changes in type 1 diabetes mellitus (van Duinkerken et al., 
2017), and cognitive dysfunction and physical disability in multiple sclerosis 
(Schoonheim et al., 2014).  
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The aim of this study was to evaluate and compare the consequences of 
PD on the resting-state functional connectivity on a whole-brain level of integrated 
networks and on eight explicit brain networks. We hypothesized that these 
combined approaches can identify regionally specific differences in functional 
connectivity of the brain between PD patients and control subjects. 
 
PATIENTS AND METHODS 
Study design and participants 
The present cross-sectional study in PD patients is part of the Profiling Parkinson’s 
disease (PROPARK) study. PD patients were recruited from the outpatient clinic for 
Movement Disorders of the Department of Neurology of the Leiden University 
Medical Center (LUMC; Leiden, the Netherlands) and nearby university and 
regional hospitals. All participants fulfilled the United Kingdom Parkinson’s Disease 
Society Brain Bank criteria for idiopathic Parkinson’s disease (Gibb and Lees, 1988). 
Evaluations occurred between January 2013 and 2016. Exclusion criteria were: 
previous or other disorders of the central nervous system, peripheral nerve 
disorders influencing motor and/or autonomic functioning, and psychiatric 
comorbidity not related to PD. Patients were matched at group level for age and 
gender with a group of healthy control subjects. Control subjects were recruited 
from the Leiden Longevity study (LLS), a study set up to identify genetic and 
phenotypic determinants of longevity in healthy long-living families (Altmann-
Schneider et al., 2013).  
 
Clinical assessments 
All patients underwent standardized assessments, including an evaluation of 
demographic and clinical characteristics. Almost all patients, except for 13 
individuals (12 de novo patients, defined as dopaminergic drug-naïve patients with 
a disease duration shorter than 5 years; one other dopaminergic drug-naïve 
patient), were tested while on dopaminergic medication. The Movement Disorder 
Society unified Parkinson’s Disease Rating Scale (MDS-UPDRS) motor scale (part 
III) was used to quantify the severity of motor symptoms (Goetz et al., 2008). 
Additionally, the severity of non-dopaminergic symptoms in Parkinson’s disease 
(SENS-PD) scale was used, which is a composite score comprising three items with 
four response options (0–3) from each of the following six domains: postural 
instability and gait difficulty, psychotic symptoms, excessive daytime sleepiness, 
autonomic dysfunction, cognitive impairment and depressive symptoms (total 
range: 0–54) (van der Heeden et al., 2016). These six domains represent a coherent 
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complex of symptoms that largely do not improve with dopaminergic medication, 
that is already present in the early disease stages, and increases in severity when 
the disease advances (van der Heeden et al., 2016). Higher scores on both scales 
reflect more severe impairment. The scales for outcomes in Parkinson’s disease - 
cognition (SCOPA-COG; cognitive functioning; range 0–43) was used to assess 
cognitive performance. The SCOPA-COG is a valid and reliable instrument 
examining the following domains: memory, attention, executive functioning and 
visuospatial functioning (Marinus et al., 2003); lower scores reflect more severe 
impairment. A levodopa dose equivalent (LDE) of daily levodopa (LDE-Dopa), 
dopamine agonists (LDE-DA), as well as a total LDE was calculated according to 
the formula developed by Tomlinson et al. (Tomlinson et al., 2010). 
 
MRI acquisition 
Imaging was performed on a 3 Tesla MRI scanner (Philips Achieva, Best, the 
Netherlands). Resting-state fMRI images were acquired with the following 
parameters: repetition time = 2.2 s, echo time = 30 ms, flip angle = 80°, 37 slices, 
resulting in a voxel size of 2.75 × 2.75 × 2.72 mm, with a 10% interslice gap, 200 
volumes, scan duration 7 min and 29 s. Participants were instructed to lie still with 
their eyes closed and not to fall asleep during the scan. For registration purposes 
three-dimensional T1-weighted anatomical images were acquired with the 
following parameters: repetition time = 9.8 ms, echo time = 4.6 ms, flip angle = 8°, 
FOV 220 × 174 × 156 mm, 130 slices with a slice thickness of 1.2 mm with no gap 
between slices, resulting in a voxel size of 1.15 × 1.15 × 1.20 mm. Additionally, a 
high resolution echo planar image was obtained with the following parameters: 
repetition time = 2.2 s, echo time = 30 ms, flip angle =80°, 84 slices, resulting in a 
voxel size of 1.96 × 1.96 × 2.00 mm with no gap between slices. 
 
Data analysis  
Before analysis, all MRI scans were visually checked to ensure that no major artifacts 
or abnormalities were present in the data. Analyses were done using the software 
provided using the FMRIB’s software library (FSL; version 5.0.8, Oxford, United 
Kingdom) and Matlab software (version 6.1, The MathWorks Inc., Natick, MA, 
2000)(Smith et al., 2004). 
 
Preprocessing 
The preprocessing of the resting-state fMRI data consisted of motion correction 
using motion correction FMRIB’s linear image registration tool (MCFLIRT) 
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(Jenkinson et al., 2002a), brain extraction (Smith, 2002), spatial smoothing using a 
Gaussian kernel with a full width at half maximum of 5 mm, high-pass temporal 
filtering with a cutoff frequency 0.01 Hz, non-linear registration with Boundary-
Based Registration to the 2 mm isotropic Montreal Neurological Institute -152 
standard space image (MNI; Montreal, QC, Canada) and a 10 mm warp resolution 
(Greve and Fischl, 2009), via the T1-weighted images, using high-resolution echo 
planar images for an additional registration step between functional images and 
T1-weighted images (Andersson et al., 2007). ICA-based Automatic Removal Of 
Motion Artifacts (ICA-AROMA) was used to identify and remove residual motion-
related artifacts from the resting-state data (Pruim et al., 2015a, 2015b). 
 
Eigenvector centrality mapping 
ECM was used to identify prominent nodes in the whole brain network per group. 
Localized differences between PD patients and control subjects were subsequently 
calculated. Each voxel is assigned its own value of relevance to the network 
(Lohmann et al., 2010). Higher EC indicates a more prominent role in the brain 
network hierarchy and lower EC a less prominent role. For each participant, we 
calculated a whole brain eigenvector centrality map in standard space, using the 
fast ECM algorithm (Binnewijzend et al., 2014; Wink et al., 2012). The EC maps of 
all participants (i.e., PD patients and control subjects) were concatenated into a 
single four-dimensional data set. A gray matter mask was applied to make sure that 
only gray matter centrality was studied. FSL-Randomise permutation-testing tool 
for nonparametric permutation inference was used for statistical analysis, with 5000 
permutations (Winkler et al., 2014). Group differences in mean EC values were 
calculated using a two-sample T-test. The threshold-free cluster enhancement 
(TFCE) technique was used to correct for multiple comparisons across space. 
Statistical threshold was set at p < 0.05, familywise error (FWE) corrected, applying 
a minimum cluster size of 40 mm3 (Smith and Nichols, 2009). 
 
Resting-state networks  
Eight standard resting-state networks were used as a template to study whole-
brain functional connectivity in a standardized way: (1) medial visual network; (2) 
lateral visual network; (3) auditory system network; (4) sensorimotor system 
network; (5) default mode network; (6) executive control network; (7 and 8) dorsal 
visual stream networks (Beckmann et al., 2005; Hafkemeijer et al., 2015). Resting-
state functional connectivity was studied using the dual regression method of FSL 
(Beckmann et al., 2009), according to Hafkemeijer et al. (2015). In short, this 
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method results in ten three-dimensional images per individual (eight resting-state 
networks and a white matter and cerebrospinal fluid template to further account 
for noise) with voxel-wise z-scores representing the functional connectivity in each 
of the templates (Hafkemeijer et al., 2015). Voxel-wise group differences between 
spatial maps of PD patients and control subjects were tested using FSL-Randomise 
using the same design as in the ECM analysis, TFCE-FWE corrected and a statistical 
threshold of p < 0.05 (Smith and Nichols, 2009; Winkler et al., 2014). The standard 
resting-state networks were used as masks in the analyses. 
 
Statistical analysis 
The following statistics were performed in SPSS (IBM SPSS Statistics for Mac, 
Version 23.0. Armonk, NY: IBM Corp.). Differences in demographic data between 
patients and control subjects were analyzed with an independent-sample T-test 
(age) and a chi-square test (gender). For brain areas with significant group 
differences in EC, mean EC values were extracted. Z-scores were extracted from 
brain areas with significant group differences in resting-state functional 
connectivity networks. Within the PD group, relationships between mean 
functional connectivity measures (i.e., mean EC values and z-scores; dependent 
variable) and the MDS-UPDRS motor score, SENS-PD score and SCOPA-COG were 
studied using a general linear model. Age, gender and gray matter volume, 
normalized for subject head size as estimated with structural image evaluation 
using normalization of atrophy cross-sectional (SIENAX) (Smith et al., 2004), were 
included as covariates in the model (Oakes et al., 2007). Relationships were 
subsequently studied within the group of PD patients who used dopaminergic 
medication, while adjusting for the total LDE. Bonferroni correction was applied to 
account for multiple comparisons.  
 
RESULTS 
Demographic characteristics 
In total, one hundred and sixty-five subjects, of which one hundred and seven 
patients and fifty-eight control subjects were included in the analysis. Demographic 
and clinical data of all participants are shown in table 1. There were no significant 
differences in age (p = 0.605) and gender (p = 0.206) between the patient and the 
control group. 
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Table 1. Main characteristics of participants 
 PD patients Control subjects 
N 107 58 
Men/women (% men) 68/39 (63.6) 31/27 (53.4) 
Age, years 64.6 (6.9) 65.2 (7.5) 
Disease duration, years 9.5 (4.8) n/a 
MDS-UPDRS motor score (0-132) 33.2 (15.5) n/a 
SENS-PD, n=99 (0-54) 13.5 (6.1) n/a 
SCOPA-COG, n=100 (0-43) 27.5 (5.8) n/a 
Total LDE, mg/day, n=92 995.6 (550.4) n/a 
Drug-naïve patients, n=1  n/a n/a 
De novo patients*, n=12  n/a n/a 
LDE-Dopa, mg/day, n=92 739.8 (486.4) n/a 
LDE-DA dose, mg/day, n=92 184.6 (208.2) n/a 
Values are means (standard deviation) for continuous variables and numbers for dichotomous 
variables. For all measurement instruments, the score range is presented in parentheses. MDS-
UPDRS: Movement Disorder Society unified Parkinson’s disease rating scale; SENS-PD: severity 
of non-dopaminergic symptoms in Parkinson’s Disease; SCOPA-COG: SCOPA cognition; LDE: 
Levodopa dosage equivalent; DA: dopamine agonists; n/a: not applicable.  
⁎ De novo patients: drug-naïve patients with disease duration shorter than five years. 
 
Eigenvector centrality maps  
Mean eigenvector centrality maps 
The mean EC group map of control subjects and the mean EC group map of PD 
patients both showed highest cortical mean EC values in the precuneus, posterior 
cingulate gyrus and occipital lobe. In the control group, highest subcortical mean 
EC values were found in the thalamus, hippocampus and caudate nucleus. In the 
patient group, highest subcortical mean EC values in patients were found in the 
thalamus and hippocampus.  
 
Patient – control subject comparisons (figure 1) 
Compared to control subjects, PD patients had increases in EC in large areas of 
the parietal and frontal lobe (opercular cortex, superior division of the lateral 
occipital cortex, posterior cingulate gyrus, precuneus, superior parietal lobe, 
supplementary motor area (SMA), pre- and postcentral gyrus, frontal gyrus and 
right middle frontal gyrus), right temporal lobe, right thalamus and a small region 
of the right hippocampus (figure 1, red areas).  
Further, compared to control subjects, patients had areas of decreased EC 
in the occipital lobe (cuneus, intracalcarine cortex, lingual gyrus, occipital pole), 
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frontal lobe (frontal gyrus, frontal medial cortex, anterior cingulate gyrus, 
paracingulate gyrus, and frontal pole), inferior division of the lateral occipital 
cortex, precuneus and right pallidum and anterior putamen (figure 1).  
We found no significant relations between mean EC values of brain areas 
with group differences and the MDS-UPDRS motor score, SENS-PD score, or 
SCOPA-COG score. 
 
 
Figure 1. Significant group differences between patients and control subjects in mean EC 
values. Red: clusters of increased EC in patients compared to control subjects. Blue: clusters 
of decreased EC in patients compared to control subjects. Results are corrected for age, 
gender and voxel-wise grey matter volume per subject. Images are overlaid on the most 
informative, sagittal, coronal, and axial slices of the MNI standard anatomical image (MNI 
coordinates of each slice are given). 
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Resting-state network analyses  
Voxel-wise group comparisons of the resting-state network connectivity revealed 
group differences in functional connectivity between PD patients and control 
subjects in seven out of eight resting-state networks (figure 2). Group differences 
were most pronounced in the medial and lateral visual network and the 
sensorimotor system network (figure 2, network 1, 2, and 4). Increased functional 
connectivity in PD patients compared to control subjects was found between the 
cuneus, precuneus, superior division of the lateral occipital cortex, intra- and 
supracalcarine cortex and lingual gyrus, and the medial visual network; between 
the superior parietal lobe, superior division of the lateral occipital cortex, lingual 
gyrus, occipital pole and the lateral visual network; and between the superior 
parietal lobe, SMA, pre- and postcentral gyrus, precuneus, cingulate gyrus, 
supramarginal gyrus and the sensorimotor system network (figure 2, network 1, 2, 
and 4). Smaller regions of increased connectivity were found between the 
precuneus, superior division of the lateral occipital cortex and the default mode 
network (DMN) and right frontoparietal network (figure 2, network 5 and 7); and 
between the superior division of the lateral occipital cortex, angular gyrus, 
supramarginal gyrus, subcallosal cortex, superior parietal lobe and the left 
frontoparietal network (figure 2, network 8).  
Decreased functional connectivity in PD patients compared to control 
subjects was found between the insular cortex, opercular cortex, frontal orbital 
cortex, precentral cortex, right putamen and the auditory system network; 
between the superior division of the lateral occipital cortex and the right 
frontoparietal network; and between the frontal orbital cortex and frontal gyrus 
and the left frontoparietal network (figure 2, network 3, 7, and 8). No changes in 
functional connectivity were observed in the executive control network (figure 2, 
network 6). 
We found no significant relations between mean z-scores of regions with 
group differences and clinical data after applying correction for multiple 
comparisons. 
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Figure 2. Significant group differences in functional connectivity between Parkinson’s 
disease patients (PD) and control subjects (HC) in resting state networks. Analyses were 
adjusted for age, gender and voxel-wise grey matter volume per subject. Yellow: Spatial 
maps of eight standard resting state networks. Increased (red) and decreased (blue) network 
connectivity in patients compared to control subjects. Images are overlaid on the most 
informative, sagittal, coronal, and axial slices of the MNI standard anatomical image (MNI 
coordinates of each slice are given).  
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DISCUSSION 
We used two complementary methods to analyze resting-state brain functional 
connectivity to study the cerebral functional reorganization at a network and whole 
brain level in patients with PD. Using a novel graph analysis approach (ECM), we 
found that frontoparietal regions display a stronger connectivity to the whole-brain 
network function in PD patients compared to control subjects, while a decreased 
connectivity was found for frontal and occipital areas of the brain (figures 1 and 3). 
In the resting-state networks of the brain, we found predominantly increased 
functional connectivity within the sensorimotor system and visual networks (figures 
2 and 3). Comparing both approaches highlights a partial overlap of regional 
alterations of the whole brain functional connectivity architecture in PD (figure 3). 
 
 
Figure 3. Main cortical differences (eigenvector centrality mapping and standard resting 
state network analysis results) in resting state functional connectivity between Parkinson’s 
disease patients and control subjects are shown. Orange: whole-brain functional 
connectivity differences as measured with eigenvector centrality mapping; Red: functional 
connectivity differences in relation to eight standard resting state networks; ­: increased 
functional connectivity; ¯: decreased functional connectivity. 
 
Resting-state functional connectivity in PD | 5 
 75 
Regions of increased functional connectivity in Parkinson’s disease 
Mean EC values were increased in large frontoparietal brain regions of PD patients 
(figures 1 and 3), indicating that these regions fulfill a more prominent role within 
the overall brain network of PD patients. The method used in our study counts the 
neighbors of each vertex, weighted by their centralities, while prior studies often 
used degree centrality in PD, another graph analysis technique that estimates the 
number of connections of a node. These studies showed higher frontoparietal 
connectivity in patients compared to control subjects (Göttlich et al., 2013; Zhang 
et al., 2015). It was further found that the efficiency among these connections was 
increased in PD patients (Zhang et al., 2015). The frontoparietal regions identified 
with ECM partly overlapped with increased regional functional connectivity 
identified by standard resting-state network analysis within the sensorimotor 
system network, including the sensorimotor, primary motor and premotor cortex, 
and SMA (figures 1–3). Increased resting-state functional connectivity of regions 
involved in motor control is a consistent finding in treated PD patients, which may 
suggest a role of dopaminergic medication (Göttlich et al., 2013; Onu et al., 2015; 
Prodoehl et al., 2014; Vo et al., 2017; Wu et al., 2009). Alternatively, the findings 
may reflect compensatory reorganization of basal ganglia thalamo-cortical motor 
loops (Eckert et al., 2006; Sabatini et al., 2000), since increased resting-state 
functional connectivity in frontoparietal regions has been described in PD patients 
in the “off-medication-state” as well (Zhang et al., 2015).  
A recurrent finding in this study, identified with both approaches, was 
increased functional connectivity of the precuneus and posterior cingulate cortex 
in PD patients (figures 1–3). Both brain structures are considered as highly 
connected and are key nodes in the DMN (Beckmann et al., 2005; Utevsky et al., 
2014; van den Heuvel and Sporns, 2011). Disruption of the DMN seems to be 
associated with cognitive deficits in PD patients (Baggio et al., 2015). A recent 
study further observed increased connectivity between the precuneus and 
frontoparietal regions during task conditions, suggesting that the precuneus 
simultaneous interacts with multiple brain networks depending on the cognitive 
status (Pievani et al., 2011; Utevsky et al., 2014). However, the association of 
functional connectivity within the DMN with cognitive performance in the present 
study did not survive correction for multiple comparisons. 
 
Regions of decreased functional connectivity in Parkinson’s disease 
Occipital and frontal parts of the brain showed reduced EC in PD patients, 
indicating a diminished role of these regions within the overall brain functional 
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architecture network in PD. Only two other studies applied whole brain ECM in PD. 
The first study aimed to investigate EC in depressed PD patients and also reported 
small frontoparietal regions of decreased EC in the non-depressed PD group 
scanned in the “off-medication-state,” compared to control subjects (Lou et al., 
2015). The second study investigated ECM changes in PD patients following 
surgery, and reported that penetration of electrodes in the subthalamic nucleus 
was associated with increased EC in the brainstem, which was related to motor 
improvement (Holiga et al., 2015). However, this is the first study in which whole 
brain ECM results of mild to moderate PD patients are compared to healthy control 
subjects. Resting-state fMRI studies using other techniques than ECM in PD, report 
connectivity reductions of frontal and occipital regions as well (Göttlich et al., 2013; 
Yao et al., 2015), possibly related to cognitive dysfunction (Lewis et al., 2003; 
Vossel et al., 2014). 
In Alzheimer’s disease, ECM shows decreased EC in the occipital cortex, 
but increased EC in frontal brain areas (Binnewijzend et al., 2014). Decreased 
occipital EC was associated with a poorer cognitive performance in Alzheimer’s 
disease patients, as well as in control subjects (Binnewijzend et al., 2014). In PD, 
decreased EC of the occipital cortex of patients may further be related to 
disruption of visual networks (Göttlich et al., 2013; Onu et al., 2015). Distinct spatial 
regions of the visual system that were identified with ECM, showed increased intra-
network connectivity in PD patients within standard resting-state visual networks in 
this study (figures 2 and 3). Collectively, these findings suggest disrupted visual 
network organization and integration, which could be related to visual deficits or 
visuo-spatial attention deficits (Beckmann et al., 2005; Tessitore et al., 2012; Vossel 
et al., 2014). 
 
Spatial distribution of altered functional connectivity  
The regions of altered functional connectivity identified with two complementary 
techniques in this study are shown in figure 3. Post mortem studies show that 
neocortical deposition of Lewy pathology occur in the temporo-occipital, temporal 
and frontal gyrus and the cingulate, insular and inferior parietal cortex (Jellinger, 
2012; McCann et al., 2016). We found altered functional connectivity in these 
structures with known Lewy pathology, but predominant regions of altered 
functional connectivity were located posterior in the brain, in particular the 
precuneus and posterior cingulate cortex. If the regionally altered functional 
connectivity in PD reflects the selective vulnerability of neuronal regions of the 
brain to alpha-SynA, cannot be assessed from this study. However, it is of interest 
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that it was shown that the majority of alpha-SynA are not localized in Lewy bodies, 
but are in the form of much smaller aggregates than Lewy bodies (Schulz-Schaeffer, 
2015, 2010). These alpha-SynA were detected throughout the cortex of Lewy body 
disease patients and were most dense in the cingulate cortex (Schulz-Schaeffer, 
2015, 2010). In PD, smaller alpha-SynA than Lewy bodies can also be observed at 
predilection sites (Schulz-Schaeffer, 2015, 2010). 
The identified posterior brain regions further showed highest mean EC 
values in healthy control subjects, which is in line with findings of other studies 
reporting these regions as highly connected (hub) regions (Binnewijzend et al., 
2014; Buckner et al., 2009; van den Heuvel and Sporns, 2011). In Alzheimer’s 
disease patients, positon emission tomography amyloid imaging showed high 
levels of amyloid beta deposition in cortical hubs compared to control subjects 
(Buckner et al., 2009). It is proposed that cortical hub regions display a preferential 
vulnerability to pathology in neurodegenerative diseases, due to their intrinsic high 
activity level, or due to the possibility that increased neuronal activity enhances the 
process of misfolded protein in the brain (Buckner et al., 2005; de Haan et al., 2012; 
Pievani et al., 2014; Surmeier et al., 2017). Noninvasive imaging of alpha-SynA has 
proven more challenging than imaging amyloid-b deposition, making it difficult to 
study the presence and density of alpha-SynA levels in specific cortical (hub) 
regions and test these assumptions in PD.  
 
Increased functional connectivity: pathogenic and compensatory mechanisms 
A prominent finding in this study is the increased functional connectivity in PD 
patients. Increased functional connectivity is a common finding in neurodegen-
erative diseases (Gregory et al., 2017; Pievani et al., 2014), but the mechanism 
underlying increased functional connectivity is unclear. It may simply reflect the 
primary disease process, or appear secondary in response to altered function 
elsewhere in the brain (Grady, 2008). The latter is often explained as a 
compensation mechanism in fMRI resting-state and task-based studies that found 
increased connectivity associated with lower symptom scores (Gregory et al., 2017; 
Pievani et al., 2014). In PD, for instance, there is evidence for increased functional 
connectivity between the putamen and the cerebellum in mild to moderate stages 
of the disease, correlating with better motor performance (Simioni et al., 2016). In 
the presence of manifested disease, as in our patient group, increased connectivity 
can indicate unsuccessful or only partial compensation (Pievani et al., 2014) In this 
study, we found an altered balance of functional brain connectivity in symptomatic 
stages of PD in which alpha-SynA pathology involves neocortical areas (Jellinger, 
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2012; McCann et al., 2016). Longitudinal fMRI studies are needed to assess if 
assumingly preserved neuronal areas show increased connectivity early in the 
disease process, if connectivity in these regions changes as the disease progresses, 
and if this is related to network levels of clinical performance. 
 
Potential limitations 
Patients were scanned while taking their usual medications in this study. A potential 
modulatory role of dopaminergic medication cannot be ruled out. Several fMRI 
studies have reported a normalizing effect of dopaminergic medication on 
connectivity in PD, especially of sensorimotor regions, which might suggest that 
our findings would have been more pronounced if patients were scanned in the 
“off-medication-state” (Tahmasian et al., 2015). Moreover, dopaminergic 
medication may lead to prolonged motor responses and its chronic use may alter 
brain organization (Anderson and Nutt, 2011; Kaasinen et al., 2003). Hence, if 
scanning PD patients after a certain period of withdrawal of dopaminergic drugs 
solely measures the influence of the disease process, is still open for debate. 
Further, scanning patients in the “on-medication-state” may reduce motion-
related artifacts, which are especially problematic in resting-state fMRI studies. To 
reduce motion related artifacts, we additionally visually inspected the data, 
performed standard motion correction and included white matter and 
cerebrospinal fluid templates in the analyses (Jenkinson et al., 2002; Pruim et al., 
2015a, 2015b). 
After strict correction for multiple comparisons, we found no relationship 
between functional connectivity and severity of motor symptoms (MDS-UPDRS 
motor scale), predominantly non-motor (non-dopaminergic) symptoms (SENS-PD 
scale) and cognition (SCOPA-COG scale) in PD. Dopaminergic medication may 
have attenuated the examined associations through a decrease of symptom scores 
that are responsive to dopaminergic stimulation and through a possible 
normalizing effect on functional connectivity in PD (Tahmasian et al., 2015). 
However, we used LED as an additional covariate in our model and this did not 
alter the significance of our findings. Moreover, no relations were found between 
functional connectivity measures and clinical measures. Previous studies in PD 
using structural imaging methods used to study brain atrophy or changes of white 
matter tracts (fractional anisotropy or mean diffusivity), however have revealed 
moderate clinico-imaging relationships (de Schipper et al., 2017; Pievani et al., 
2011; Zhang et al., 2016). This likely suggests that changes of the functional 
connectivity architecture of the brain provide a different perspective of the 
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consequences of the pathobiology of PD, which do not necessarily have to be 
associated with clinical measures. This assumption is in line with studies in other 
neurodegenerative diseases, such as Alzheimer’s disease, progressive nuclear 
palsy and Huntington’s disease, where no clear associations have yet emerged 
between measures of functional connectivity and clinical measures of disease 
severity (Pievani et al., 2011). 
 
Conclusion 
The findings in this study on functional brain network organization in PD indicate a 
diminished role of frontal and occipital brain areas, while posterior parietal and 
frontoparietal areas display a more prominent connectivity to the whole-brain 
network function. We did not find significant correlations between clinical 
measures and functional imaging parameters, suggesting that changes on the level 
of functional connectivity architecture of the brain provide a different perspective 
of the pathological consequences of PD. Regionally altered functional connectivity 
was most pronounced in highly connected (hub) regions, particularly the posterior 
cingulate cortex and precuneus, which may account for the distributed 
abnormalities across the whole brain network architecture in PD.  
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ABSTRACT 
 
Introduction: Recent research shows that resting-state fMRI data in combination 
with machine-learning techniques can be used to distinguish patients with 
neurodegenerative disease, like Alzheimer’s disease, from healthy control subjects. 
We aimed to explore the potential of an elastic net model to recognize Parkinson’s 
disease (PD) patients (at an individual level) using resting-state fMRI. 
 
Methods: We used resting-state fMRI scans from 114 PD patients and 58 age- and 
sex-matched healthy control subjects. We calculated functional connectivity 
matrices and dynamics for full and partial correlations, resulting in four feature 
types, which have been used separately as well as combined in a cross-validated 
elastic net regularized logistic regression. We calculated the area under the curve 
to determine classification performance.  
 
Results: The area under the curve values ranged between 0.752 and 0.858. Highest 
values were found for partial correlation functional connectivity dynamics. We also 
investigated whether particular clinical features contributed to the individual 
classification scores of PD patients and no associations were found.  
 
Conclusion: These results show that resting-state functional connectivity dynamics 
in an elastic net regression is a promising method to differentiate between 
PD patients and healthy control subjects at an individual level.  
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INTRODUCTION 
Parkinson’s disease (PD) is the most common neurodegenerative disorder after 
Alzheimer’s disease (AD), and its prevalence is growing (De Rijk et al., 2000; Dorsey 
et al., 2018). The clinical spectrum of PD comprises a broad range of motor and 
non-motor symptoms (Chaudhuri et al., 2006). Patients show conspicuous 
differences in the course or occurrence of symptoms, the severity of symptoms, as 
well as in the progression rate of the disease (Foltynie et al., 2002). The 
heterogeneity of PD can complicate diagnosis in clinical practice. Adding to the 
complexity of early diagnosis is the long pre-symptomatic phase of the disease, 
when neurodegeneration has commenced, but the (motor) symptoms are yet 
insufficient to define PD (Berg et al., 2015).  
Resting-state functional magnetic resonance imaging (fMRI) of the brain 
might have the potential to identify early PD or persons at risk, before overt 
expression of the disease. Resting-state fMRI data of PD patients have shown 
differences between PD patients and control subjects in functional connectivity (de 
Schipper et al., 2018). Furthermore, a recent study showed changes in PD patients 
in the variations of functional connectivity over a short time (dynamics) (Kim et al., 
2017). However, these results represent group-wise comparisons and are not 
applicable to individual patients with PD. In AD, resting-state fMRI research has 
shown promising results in distinguishing patients and control subjects at an 
individual level through classification approaches that enable the incorporation of 
numerous functional connectivity parameters as predictors into one model and 
automatically select the most relevant ones (de Vos et al., 2018; Schouten et al., 
2016).  
The aim of the present study is to investigate whether resting-state fMRI 
data can be used to classify PD patients and healthy control subjects. We calculated 
whole-brain functional connectivity using full and partial correlations, and 
calculated functional connectivity dynamics using a sliding window approach 
(Hutchison et al., 2013). These features were used as input for machine-learning 
techniques to calculate classification scores for each measure (full and partial 
functional connectivity matrices and dynamics) separately and all measures 
combined in order to determine the most accurate prediction model. We further 
investigated whether classification scores were correlated to clinical measures of 
PD.  
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METHODS 
Study design and participants 
The sample for the current study consists of 172 participants: 114 PD patients, of 
which 11 patients were diagnosed as PD with Lewy bodies (DLB) subtype, and 58 
healthy control subjects. In line with the most recent MDS-PD criteria, we qualified 
patients with DLB who met the clinical criteria for PD, as PD (Gibb and Lees, 1988; 
Postuma et al., 2015). Patients were recruited from the outpatient clinic for 
Movement Disorders of the Department of Neurology of the Leiden University 
Medical Center (LUMC; Leiden, the Netherlands) and nearby university and 
regional hospitals. PD patients fulfilled the United Kingdom Parkinson’s Disease 
Society Brain Bank criteria for idiopathic Parkinson’s disease (Gibb and Lees, 1988) 
and DLB patients the McKeith DLB diagnostic criteria for probable DLB (McKeith 
et al., 2005). Exclusion criteria were previous or other disorders of the central 
nervous system, peripheral nerve disorders influencing motor and/or autonomic 
functioning, and psychiatric comorbidity not related to PD. Control subjects were 
selected from the Leiden Longevity Study (Altmann-Schneider et al., 2013), 
matched at group level for age and gender with the PD patients. 
 
Clinical measures 
The Movement Disorder Society unified Parkinson’s disease rating scale (MDS-
UPDRS) motor scale (part III) was used to quantify the severity of motor symptoms 
(Goetz et al., 2008). Fluctuating cognition and recurrent visual hallucinations are 
two core features of DLB, besides spontaneous features of parkinsonism (McKeith 
et al., 2005). We therefore included measures of cognition and hallucinations to 
our examinations as well. The mini-mental state examination (MMSE) was used to 
assess cognitive performance (Folstein et al., 1975). We quantified hallucinations 
using the hallucination item of the SCOPA psychiatric complications (PC, range: 0 
-18) scale (Visser et al., 2007). We further used the severity of non-dopaminergic 
symptoms in Parkinson’s disease (SENS-PD) scale to measure symptoms that 
largely do not improve with dopaminergic medication (Goetz et al., 2008; van der 
Heeden et al., 2016). The SENS-PD is a composite score comprising three items 
with four response options (range: 0-3) from each of the following six domains: 
postural instability and gait difficulty, psychotic symptoms, excessive daytime 
sleepiness, autonomic dysfunction, cognitive impairment and depressive 
symptoms (total range: 0-54) (van der Heeden et al., 2016). These six domains 
represent a coherent complex of symptoms that may already be present in the 
early disease stages, and increases in severity when the disease advances (van der 
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Heeden et al., 2016). Higher scores reflect more severe impairment. The formula 
of Tomlinson et al. was used to calculate a levodopa equivalent dose (LDE) of daily 
levodopa (Tomlinson et al., 2010). 
 
fMRI acquisition 
Imaging was performed on a 3 Tesla MRI scanner (Philips Achieva, Best, the 
Netherlands). Participants were instructed not to fall asleep during the scan and to 
lie with their eyes closed without moving. The following parameters were used for 
the resting-state fMRI scans: repetition time = 2.2 s, echo time = 30 ms, flip angle 
= 80°, 37 slices, resulting in a voxel size of 2.75 × 2.75 × 2.72 mm, with a 10% 
interslice gap, 200 volumes, scan duration 7 min and 29 s. Three-dimensional T1-
weighted anatomical images were obtained with the following parameters: 
repetition time = 9.8 ms, echo time = 4.6 ms, flip angle = 8°, FOV 220 × 174 × 156 
mm, 130 slices with a slice thickness of 1.2 mm with no gap between slices, 
resulting in a voxel size of 1.15 × 1.15 × 1.20 mm. A 32-channel and an 8-channel 
head coil was used for the PD group and the control group respectively. 
 
Resting-state fMRI preprocessing  
Resting-state fMRI data was preprocessed applying: motion correction with the 
motion correction FMRIB's linear image registration tool (MCFLIRT) (Jenkinson et 
al., 2002a), brain extraction (Smith, 2002) and spatial smoothing using a Gaussian 
kernel with a full width at half maximum of 5 mm. Preprocessing further consisted 
of high-pass temporal filtering with a cutoff frequency 0.01 Hz and finally a non-
linear registration with boundary-based registration to the 2 mm isotropic Montreal 
Neurological Institute standard space image (MNI; Montreal, QC, Canada) and a 
10 mm warp resolution (Greve and Fischl, 2009), via the T1-weighted images, using 
high-resolution echo planar images for an additional registration step between 
functional images and T1-weighted images (Andersson et al., 2007; de Schipper et 
al., 2018). We further used independent component analysis based automatic 
removal of motion artifacts (ICA-AROMA) to identify and remove residual motion-
related artifacts data (Pruim et al., 2015a, 2015b). The resting-state fMRI scan was 
subsequently weighted by a gray matter probability map, because neuronal activity 
predominantly takes place in gray matter voxels. The Harvard-Oxford cortical 
structural atlas (as provided by FSL version 5.0) was used to separate the 
preprocessed scans into 48 different brain regions. Time courses for each of the 48 
brain regions were calculated for each subject, which were subsequently used in 
the functional connectivity analyses. 
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Functional connectivity matrices  
We used the time courses of the 48 brain regions to calculate functional 
connectivity matrices, using both full and sparse partial correlations. Whereas full 
correlations represent the total correlation between two brain regions, sparse 
partial correlations focus on the unique correlation between two regions (Peng et 
al., 2009). Sparse partial correlations were calculated using the graphical lasso 
algorithm implemented in R package “glasso” (Friedman et al., 2010). For each 
subject we calculated both full and sparse partial correlations between all pairs of 
brain regions, resulting in two functional connectivity matrices both consisting of  (48	 • 	 (48	– 	1))/2		 = 1128 correlations.  
 
Functional connectivity dynamics  
The dynamics of the above described functional connectivity matrices were 
calculated, using a sliding window approach (Chang and Glover, 2010; Hutchison 
et al., 2013; Jones et al., 2012), in which functional connectivity is calculated within 
a limited time window. This window was shifted over the total length of the scan 
and the standard deviation over all these windows was calculated. The size of the 
window was set at 11 scan volumes, which equals 24.7 seconds, and was slided 
one volume at a time. Functional connectivity dynamics was calculated for both the 
full and sparse partial correlation matrices, resulting in two functional connectivity 
dynamics matrices both consisting of  (48	 • 	 (48	 − 	1))/2		 = 1128 correlations. 
 
Statistical analyses 
The full and partial functional connectivity and dynamical matrices were used as 
input for elastic net regularized logistic regression models in order to classify 
subjects as either control subject (0) or PD patient (1). Elastic net regularized 
logistic regression has been commonly used for neuroimaging classifications 
studies (de Vos et al., 2018; Schouten et al., 2016; Teipel et al., 2017, 2015). We 
performed elastic net regularized logistic regression with all feature types 
separately as input, as well as with all feature types combined. In elastic net 
regression, only the most relevant predictors will enter the regression model 
(Friedman et al., 2010; Zou and Hastie, 2005). Elastic net regression uses a 
combination of an L1-regularisation (lasso) (Tibshirani, 1996) and an L2-
regularisation (ridge) (Hoerl and Kennard, 1970) and compromises between the 
two (Zou and Hastie, 2005). R package “glmnet” was used for the elastic net 
analyses (Friedman et al., 2010).  
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We used nested cross-validation to ensure that we were not overfitting the 
classification model. The inner cross validation loop was used to tune the sizes of 
the L1 and L2 penalties, and the ratio between those two penalties. The outer cross 
validation loop was used to train and evaluate the classification model. For both 
the inner and outer cross validation loop we used tenfold cross-validation, where 
the data was split repeatedly into ten percent test set and ninety percent training 
set, making sure each part of the data had been used as test set once. The training 
set in the outer cross validation loop was used for the inner cross validation loop 
(figure 1). The whole cross validation procedure was repeated ten times in order 
to reduce the variability resulting from the random partitioning of subjects into 
training and test folds. 
 
 
Figure 1. Cross-validation approach. Repeated, nested, tenfold cross-validation represent-
ted schematically. Green bars represent the test set, blue bars represent the training set. In 
reality, it was randomly chosen in which fold each of the subjects was part of the test or 
training set, making sure each of the subjects was only part of the test set once. For the 
purpose of the figure, however, the test and training set are portrayed as fixed blocks. 
 
As the current study has an unbalanced design, we used receiver operator 
characteristic (ROC) curves to measure classification performance, as this method 
controls for unbalanced groups. The ROC curve was first computed and 
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subsequently the area under the curve (AUC) was calculated using the R-package 
“auc” (Balling & Van den Poel, 2013). Since there was no clear preference for a 
lower number of false positive diagnoses or a lower number of false negative 
diagnoses, the cut-off value to calculate the sensitivity and specificity was 
determined for each feature type individually, and was based on the Youden Index. 
This index reflects the value at which the sum of the sensitivity and the specificity 
is the highest (Fluss et al., 2005). The classification accuracy, sensitivity, and 
specificity were calculated for all features separately and combined.  
Within the group of PD patients, we investigated the relationship between 
clinical variables (disease duration, MDS-UPDRS motor, SENS-PD and MMSE 
scores, hallucinations) and classification scores of the most accurate classification 
model using linear regression models (IBM SPSS Statistics for Mac, Version 23.0. 
Armonk, NY: IBM Corp.). The relationship between classification scores of the most 
accurate classification model and total LDE was investigated within the group of 
PD patients on dopaminergic medication. We also investigated group differences 
in classification scores of the most accurate classification model between drug-
naïve patients and patients on dopaminergic medication using an independent-
samples t-test. Bonferroni correction was applied in all cases. 
 
RESULTS 
Demographic data of the PD patients and healthy control subjects and clinical data 
of the PD patients are shown in table 1. Gender and age did not significantly differ 
between the patient and control group. 
 
Classification accuracy 
In table 2 the average AUC values over all cross-validation repetitions per feature 
type are shown. Combining all types resulted in an average classification accuracy 
of 0.818. Using the types of features separately resulted in a higher average 
classification accuracy for both partial correlation features, that is 0.832 for partial 
correlation functional connectivity and 0.858 for partial correlation functional 
connectivity dynamics, which is the highest AUC value obtained in the current 
study. Combining all types of features did not yield a higher AUC value than using 
all types of features separately. The individual predictions of the subjects are 
plotted in figure 2. 
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Table 1. Main characteristics of participants 
 Patients Control subjects 
N 114 58 
Men/women 74/40 (64.9) 31/27 (53.4) 
Age, years 65.3 (7.0) 65.2 (7.5) 
Disease duration, years 8.8 (4.7) n/a 
MDS-UPDRS motor score (0-132) 32.9 (15.3) n/a 
SENS-PD (0-54) 14.2 (6.4) n/a 
MMSE 28.0 (2.6) n/a 
SCOPA PC hallucination item (0-3) 4a n/a 
Total LDE, mg/dayb 954.9 (570.9) n/a 
Drug-naïve patients 20 n/a 
Values are means (standard deviation) for continuous variables and numbers for gender (% men). 
For all measurement instruments, the score range is presented in parentheses. MDS-UPDRS: 
Movement Disorder Society unified Parkinson’s disease rating scale; SENS-PD: severity of non-
dopaminergic symptoms in Parkinson’s disease; MMSE: mini-mental state examination; LDE: 
Levodopa dosage equivalent; n/a: not applicable.  
a 4 Patients had a score > 1, range: 0–3; b N = 94 (20 patients were drug-naïve). 
 
 
Correlations with clinical scores 
We investigated the relationship between individual elastic net partial correlation 
functional connectivity dynamics classification scores of the PD patients and clinical 
variables, but after correction for multiple comparisons, no statistically significant 
associations were found. The mean classification scores between drug-naïve 
patients (0.77) and patients on dopaminergic medication (0.83) did not significantly 
differ between groups (p = 0.205). 
 
 
 
 
 
 
Table 2. Mean AUC, sensitivity and specificity 
 FFC PFC FFD PFD All 
AUC 0.752  0.832  0.753  0.858 0.818 
Sensitivity 0.655 0.828 0.709 0.809 0.831 
Specificity  0.781 0.778 0.744 0.822 0.705 
AUC: area under the curve; FFC: full correlation functional connectivity; PFC: partial correlation 
functional connectivity; FFD: full correlation functional connectivity dynamics; PFD: partial 
correlation functional connectivity dynamics; All: FFC, PFC, FFD and PFD combined. 
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Figure 2. Classifications per feature type against diagnosis. FFC = full correlation functional 
connectivity, PFC = partial correlation functional connectivity, FFD = full correlation func-
tional connectivity dynamics, PFD = partial correlation functional connectivity dynamics, ALL 
= FFC, PFC, FFD and PFD combined. 
 
DISCUSSION 
We studied the accuracy of different resting-state fMRI measures in combination 
with machine-learning techniques for the (individual) classification of PD patients. 
Full and partial functional connectivity matrices and dynamics were computed and 
used as input in an elastic net regression to discriminate PD patients from healthy 
control subjects. For both the functional connectivity matrices and dynamics, 
partial correlations resulted in higher classification accuracy than full correlations. 
The functional connectivity dynamics resulted in a (slightly) higher classification 
accuracy than the functional connectivity matrices. Combining multiple feature 
types did not improve the classification accuracy compared to using the features 
separately.  
The partial functional connectivity dynamics model resulted in an AUC of 
0.86. Previous MRI studies that investigated machine learning techniques in PD, 
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have used T1-weighted MRI data for differentiation of PD from control subjects, 
patients with progressive supranuclear palsy or subjects with scans without 
evidence of dopaminergic deficit (SWEDD) (Sakai and Yamada, 2018). Previous 
studies using grey and white matter volumes of regions of interest for 
differentiation of PD and control subjects reported an overall accuracy 0.82 (Adeli 
et al., 2016) and 0.71 (Liu et al., 2016). Another study used T1-weighted MRI data 
alone as well, but incorporated structural connectivity between brain regions, and 
found an overall accuracy of 0.86 (Peng et al., 2017). A proposed approach for 
early diagnosis of PD that combined T1-weighted MRI markers with clinical scores 
typical of prodromal PD even reached an AUC value of 0.97 (Amoroso et al., 2018). 
Overall, the findings of these studies combined with our results, suggest that a 
combination of structural and functional imaging combined with machine learning 
approaches are a promising classification method for PD diagnosis, and in time 
possibly early or prodromal PD. The integration of other imaging modalities, such 
as diffusion tensor imaging (DTI), may further improve classification performances. 
The dynamic changes of functional connectivity, which is relatively new in 
the field of PD, resulted in the highest classification accuracy. In a recent study, 
functional connectivity dynamics suggested two distinct connectivity states: a more 
frequent, sparsely connected within-network state and a less frequent, more 
strongly interconnected between-network state (Kim et al., 2017). Their results 
show that PD patients spent less time in the sparsely connected state, while they 
spent more time in the more strongly interconnected state (Kim et al., 2017). This 
suggests that the connectivity state that is characterized by increased interactions 
between cerebral networks predominates in PD, at the expense of the more 
sparsely within-network state (Kim et al., 2017). Our findings stressing the 
relevance of dynamic changes in classifying patients with PD are in line with those 
from previous studies in AD (de Vos et al., 2018; Jones et al., 2012). Functional 
dynamics may reflect aspects of functional capacity of neural systems (Deco et al., 
2011; Kucyi et al., 2017), and are suggested as possible biomarkers of disease (Kim 
et al., 2017). 
For both the functional connectivity matrices and dynamics, partial 
correlations resulted in higher classification accuracy than full correlations. As 
partial correlations are controlled for the potential effect of other brain regions on 
that relation (Peng et al., 2009), they provide unique information of the relationship 
between two brain regions and functional connectivity measures based on partial 
correlations therefore likely provide a better estimation of functional connectivity 
than full correlations (Smith et al., 2011). 
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Although the AUC value obtained for the functional connectivity dynamics 
model based on partial correlations in the current study was quite high, no 
associations with clinical variables were found. This may be attributed to the fact 
that the model was trained to differentiate PD patients from healthy control 
subjects, using a combined set of predictors selected from correlations between 
multiple brain regions, and classification scores. In turn, this approach renders the 
occurrence of correlations between partial functional connectivity dynamics and 
individual symptoms or clinical domains less likely.   
This is the first study using resting-state fMRI data in combination with 
elastic net regression analysis for (individual) classification of PD patients, resulting 
in moderate to good PD classification. Machine-learning methods could be of use 
for early diagnosis of PD, or possibly detect brain changes in persons at risk for 
developing PD. However, the patient group used to train and test the prediction 
models in this study included few de novo PD patients, had a moderate mean 
disease severity and a mean disease duration of approximately nine years. A 
population comprising a larger number of de novo patients is possibly more 
suitable for the purpose of early diagnosis of PD. Further, 92 patients in this study 
were scanned while taking their usual dopaminergic medications, while 20 patients 
were drug-naïve. The acute effect of dopaminergic medication may normalize 
functional connectivity in PD (Tahmasian et al., 2015), and its chronic use may alter 
brain organization (Anderson and Nutt, 2011; Kaasinen et al., 2003). Dopaminergic 
medication was not related to the classifications scores of our partial functional 
connectivity dynamics model, and mean classification scores did not differ between 
patients on dopaminergic medication and those who were not, but we cannot rule 
out a potential modulatory role of dopaminergic medication. A potential limitation 
of our study could be that the MRI acquisition of our two cohorts (control persons 
and patients with PD) were performed with a different type of head coil (8-channel 
versus 32-channel, respectively) (Panman et al., 2019), which might have affected 
our classification score, although another study comparing resting-state fMRI data 
using an 8- and 32-channel head coil on a 3 Tesla MRI scanner did not find 
significant differences between the two head coils (Paolini et al., 2015). Of note is 
that the scans in this study last 7 minutes and 29 seconds, and a timeframe of 24.7 
seconds was taken as one window in the sliding-window approach, which is quite 
short to calculate functional connectivity dynamics (Hindriks et al., 2016). There 
exists an arbitrary trade-off between the number of measurement moments in one 
window and the number of different windows that can be used for calculation of 
functional connectivity dynamics. In the current study, using a higher number of 
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different windows was preferred over using more measurements in one window. 
However, using larger windows may yield even better classification accuracies than 
the ones that we found in the current study (Shirer et al., 2012).  
 
Conclusion 
We showed that it is possible to achieve moderate to good PD classification using 
elastic net regularized logistic regression combined with resting-state fMRI data, in 
particular with partial functional connectivity dynamics. This approach has potential 
as a suitable method for use in future PD classification studies. 
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7 Summary, concluding remarks and future 
perspectives 
 
 
 
 
 
 
 
 
 
 
 
 
 
Summary, concluding remarks and future perspectives | 7 
 96 
In this thesis, the consequences of PD were studied using advanced approaches in 
neuroimaging, including structural as well as functional connectivity networks, 
examination of the role of aging in white matter degeneration in PD, and the use 
of machine learning classification models. Our main findings are summarized and 
discussed in the next paragraphs of this chapter, followed by possible directions 
for future research. 
 
Summary 
Chapter 1 is the introduction to this thesis. In chapter 2, we investigated the 
integrity of nine standardized structural covariance networks (SCNs) in relation to 
clinical severity of PD (Hafkemeijer et al., 2014). An SCN is based on 
interdependent regions of grey matter density. We found that two out of nine 
networks showed atrophy and a loss of integrity. We identified atrophy and loss of 
integrity in the anterior and posterior cingulate networks in PD patients. 
Abnormalities of both networks were associated with predominantly non-
dopaminergic features, specifically cognition and excessive daytime sleepiness. 
Our findings suggest that (components of) the cingulate networks display a specific 
vulnerability to the pathobiology of PD and may operate as interfaces between 
networks involved in cognition and alertness.   
 
DLB and PD are considered subtypes of the alpha-synucleinopathy spectrum that 
show similar and dissimilar clinical and morphological features. In chapter 3, we 
used the same technique as in chapter 2 (SCNs) to further our understanding of 
brain grey matter abnormalities that might differentiate PD and DLB more clearly, 
combined with voxel-based morphometry, volumetric measures and vertex-based 
shape analysis. This study showed atrophy of the hippocampus and 
parahippocampal gyrus in DLB compared with PD patients, with a differential 
involvement of the head and body of the hippocampus. Moreover, integrity of the 
posterior cingulate network, which also comprises (para)hippocampal regions, was 
significantly lower in DLB. The findings of this study show that regional 
hippocampal differences between DLB and PD may be important in the distinction 
between the two disorders.  
 
As we identified a loss of integrity and atrophy beyond the strong effects of aging 
in two SNCs (see chapter 2 for explanation), we hypothesized that there may be an 
interaction effect of age and disease presence on white matter integrity in PD and 
this was addressed in chapter 4. White matter is especially prone to the effects of 
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aging, and it is increasingly recognized that white matter is already affected in early 
stages of PD. We found a similar age-related decline of white matter integrity for 
PD patients and healthy control subjects in this study, but PD patients had more 
white matter hyperintensities (WMHs) than expected for their age. The excess of 
WMHs was partly located in periventricular and deep frontal white matter of PD 
patients, and was, besides age, related to visuospatial functioning and postural 
instability and gait difficulty. Global microstructural integrity of the normal 
appearing white matter did not differ between patients and healthy control 
subjects, suggesting that PD-specific changes do not exceed normal age-
associated change in white matter without lesions. 
 
In chapter 5, we studied PD-related changes of the brain with network approaches 
again, but with a different method. We used a novel graph analytic approach in 
functional imaging (eigenvector centrality mapping; ECM), to examine changes in 
functional brain connectivity architecture on a whole brain network level in patients 
with PD. We found that frontoparietal regions display a stronger connectivity to 
the whole-brain network function in PD patients compared with healthy control 
subjects, while a decreased connectivity was found for frontal and occipital areas 
of the brain. Additionally, we used eight standardized resting-state subnetworks of 
the brain, which pointed at predominantly increased functional connectivity within 
the sensorimotor system and visual networks. Comparing both approaches 
highlighted altered functional connectivity in highly connected (hub) regions, 
particularly in the posterior cingulate cortex and precuneus, which may account for 
the distributed abnormalities across the whole brain network architecture in PD 
patients. The regional altered functional connectivity was not related to clinical 
measures in this study, indicating that changes on the level of functional 
connectivity architecture of the brain are not necessarily associated with clinical 
measures.  
 
In chapter 6, we explored the use of machine learning techniques in combination 
with resting-state fMRI data to differentiate between PD patients and 
healthy control subjects at an individual level. We computed functional connectivity 
matrices and dynamics for full and partial correlations, resulting in four feature 
types, which have been used separately as well as combined in a cross-validated 
elastic net regularized logistic regression. We calculated the area under the curve 
(AUC) to determine classification performance. The AUC values ranged between 
0.752 and 0.858. The highest values were found for partial correlation functional 
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connectivity dynamics. We also investigated whether particular clinical features 
contributed to the individual classification scores of PD patients and no 
associations were found. We showed that it is possible to achieve moderate to 
good PD classification using elastic net regularized logistic regression combined 
with resting-state fMRI data, in particular with the use of functional connectivity 
dynamics. 
 
Concluding remarks 
Structural and functional connectivity 
Chapter 2, 3 and 5 in this thesis showed that network approaches provide valuable 
insights in the structural and functional brain architecture of patients with PD. It is 
hypothesized that neurodegenerative diseases show a selective, network-driven 
neuronal vulnerability (Seeley et al., 2009). The findings in chapter 2 and 3 showed 
specific structural network degeneration in PD and DLB, namely degeneration of 
the anterior and posterior cingulate network. The anterior cingulate network shows 
spatial overlap with a network described in a previous study that identified a 
structural network that was also degenerated in PD (Zeighami et al., 2015). The 
cortical regions in this network included the anterior cingulate cortex as well 
(Zeighami et al., 2015). Another study used this network in their analysis of 
subtypes with “mild motor-predominant”, “diffuse malignant” and “intermediate” 
PD. This study showed more pronounced atrophy in the anterior cingulate cortex 
in “diffuse malignant” PD patients compared with the other two subtypes 
(Fereshtehnejad et al., 2017). These findings indicate that the cingulate cortex is 
particularly vulnerable in PD, and that the changes in the networks in which the 
cingulate cortex is involved, relate to disease progression in PD.  
 
Further we found regionally altered functional connectivity in the precuneus and 
posterior cingulate cortex, which are important regions of the posterior cingulate 
structural connectivity network (chapter 5). The precuneus and posterior cingulate 
cortex are key nodes in the default mode network, which is a functional connectivity 
network that is frequently described to be disrupted in PD, and is possibly 
associated to cognitive deficits in PD (Baggio et al., 2014). These structures are 
considered as central and highly connected brain regions (Hagmann et al., 2008; 
van den Heuvel and Hulshoff Pol, 2010), and are suggested to be part of a set of 
posterior medial and parietal cortical regions that form a structural core of the brain 
(Hagmann et al., 2008). The structural core may have a central role in integrating 
information across structurally segregated and functionally specialized brain 
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regions (Hagmann et al., 2008). Changes in the structural core may therefore have 
widespread changes across the brain network architecture. Combined, these 
findings point out an important role of these highly connected (hub) regions in 
structural and functional covariance in PD, and connectional variability of the 
precuneus and posterior cingulate cortex may relate to specific subsets or 
characteristics of PD patients, such as our finding in chapter 2 that loss of integrity 
of the posterior cingulate network related to predominantly non-dopaminergic 
features. 
 
Age 
Several studies suggested that age is an important modulating factor in the disease 
progression and phenotype expression of PD. For example, advancing age is 
associated with a more rapid decline in motor function and more severe cognitive 
impairment in patients with PD (Alves et al., 2005; Levy, 2007). The exact role of 
aging in PD, however, and changes that underlie the relationship between age and 
PD, are unclear. Numerous neuroimaging studies have shown an age-related 
decline in MRI parameters of brain structure and function (Ferreira and Busatto, 
2013; Good et al., 2001; Hafkemeijer et al., 2012; Jernigan et al., 2001; Raz et al., 
2005; Resnick et al., 2003). Our results showed grey matter atrophy in DLB and PD 
patients compared with age-matched healthy control subjects in regions that 
explicitly show age-dependent decreased grey matter volume, such as the 
hippocampus and cingulate cortex (Good et al., 2001; Jernigan et al., 2001; Raz et 
al., 2005; Resnick et al., 2003). Further, regional altered functional connectivity was 
mainly expressed in the precuneus and posterior cingulate cortex, which are also 
regions that are associated with functional disruption at high age (Ferreira and 
Busatto, 2013; Hafkemeijer et al., 2012). These findings suggests that the 
pathobiology of PD has a preferential susceptibility for regions that are already 
affected by the aging process, or that the age-effect is possibly influenced by 
disease in a region dependent manner (Claassen et al., 2016). Our results of 
chapter 4, combined with the results of previous studies, suggest a similar age-
related decline of global white matter integrity in PD and healthy control subjects. 
The results of chapter 4 further showed that WMHs in PD may already be present 
in an early phase of the disease. This is in line with other studies suggesting that 
white matter may be affected in the very early stages of PD (Dadar et al., 2018; 
Duncan et al., 2016; Veselý and Rektor, 2016). A possible explanation could be that 
PD patients show a non-linear trajectory of an early accelerated age-related 
decline, which stabilizes with advancing age (Claassen et al., 2016).This explanation 
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is supported by the absence of any relation between disease duration and WMHs 
in chapter 4. 
 
Dopaminergic medication 
Except for a group of drug-naïve patients, the patients in the studies described in 
this thesis were scanned while taking their usual medications. MRI scanning of PD 
patients without dopaminergic treatment is problematic, as tremor may result in 
motion-related artifacts (Tahmasian et al., 2015) and participation may be 
jeopardized when patients have to travel from home during the off-state. Resting-
state fMRI is particularly prone to noise due to motion, and the effects of head 
motion should be considered when it differs between groups (van Dijk et al., 2012). 
The reduction of motor symptoms through dopaminergic treatment may reduce 
the effects of excessive involuntary head motion, in addition to the other 
approaches used in this thesis for motion artifact removal (Jenkinson et al., 2002b; 
Pruim et al., 2015a, 2015b; Tahmasian et al., 2015). However, scanning PD patients 
in the “on-medication state” may also hamper the interpretation of data since 
functional connectivity changes secondary to dopaminergic therapy may occur in 
PD patients (Tahmasian et al., 2017). fMRI studies have reported a normalizing 
effect of dopaminergic medication on abnormal functional connectivity associated 
with PD, which might suggest that our findings would have been more pronounced 
if patients were scanned in the “off-medication-state” (Tahmasian et al., 2015). The 
results of other studies suggest that dopaminergic medication may also alter the 
functional connectivity between brain regions that are not necessarily involved in 
the improvement of symptoms of PD (Ng et al., 2017). However, there is evidence 
that these effects of dopaminergic medication are small, in particular in the well-
established resting-state networks that we used in chapter 5 (Flodin et al., 2012). 
Moreover, scanning PD patients in the “off-medication-state” may result in group 
functional connectivity differences secondary to dopaminergic treatment as well, 
due to changed brain organization caused by the long-term use of dopaminergic 
medication (Kaasinen et al., 2003; Kurani et al., 2015). De novo patients are 
therefore the only population to study pathophysiology independent of 
dopaminergic therapy. In PD populations using dopaminergic treatment the 
dopaminergic state of PD patients should be considered when interpreting or 
comparing results of MRI studies. 
 
 
 
Summary, concluding remarks and future perspectives | 7 
 101 
Study population 
The research presented in this thesis was performed in a cross-sectional setting in 
PD and DLB patients. Some studies described in this thesis required the use of a 
control group. These control subjects were selected from the Leiden Longevity 
Study (Altmann-Schneider et al., 2013), which comprises a large pool of healthy 
subjects from which matched controls can be selected. It should be considered 
that there were some slight differences in some of the variables collected and the 
methods of data collection between patients and control subjects. The MRI 
acquisition in our control group and PD group was performed with a different type 
of head coil (8-channel versus 32-channel, respectively), which may have influenced 
our findings, although we used MRI approaches relatively insensitive to a potential 
coil effect (Geng et al., 2012; Panman et al., 2019; Paolini et al., 2015). However, 
the use of different head coils may hamper the analysis of MRI data and 
standardization of head coils across groups of interest is recommended in future 
study designs (Panman et al., 2019). Patients and control subjects were matched 
for age and gender, two known confounders of particular importance in MRI 
studies (Barnes et al., 2009). A critical consideration related to the control group 
selected for the study presented in chapter 4 is that control subjects were not 
matched for cardiovascular risk profile, in addition to age and gender, although it 
should be noted that patients and control subjects did not differ in those 
cardiovascular risk factors that were assessed in both the PROPARK and Leiden 
Longevity study. 
 
Future perspectives 
Multimodal neuroimaging studies 
We studied brain MRI in PD and DLB patients with five different MRI sequences in 
this thesis, which, amongst other things, highlighted a spatial overlap of altered 
structural and functional connectivity, in particular of the cingulate cortex. 
Structural and functional MRI are increasingly combined to provide more 
informative insights into both structural as well as functional connectivity in 
neurodegenerative diseases (Arbabshirani et al., 2017; Seeley et al., 2009). 
Combining data of different imaging modalities, such as MRI, Positron-Emission 
Tomography (PET), magnetoencephalography (MEG) or electroencephalography 
(EEG), may yield even more insights into the relationships between function and 
structure (Arbabshirani et al., 2017; Calhoun and Sui, 2016). In schizophrenia, 
several studies combined MRI data with EEG or MEG data (Calhoun and Sui, 2016). 
One study showed considerable spatial consistency between function (MEG) and 
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structure (white matter integrity), with regional reduced MEG amplitude and FA in 
a posterior visual network, which was related to cognitive performance (Stephen 
et al., 2013). There is increasing knowledge on the integrated analysis of 
multimodal data. The combination of deep learning and multimodal data or 
multimodal classification may reveal unique information that cannot be obtained 
when using one modality (Arbabshirani et al., 2017; Calhoun and Sui, 2016). Several 
combinations of PET and MRI results have been applied in PD and DLB, indicating 
striatal dopamine modulation of functional connectivity networks (Baik et al., 2014; 
Lebedev et al., 2014; Weingarten et al., 2015), and showing that combined data 
distinguished DLB from Alzheimer’s disease better than measurements from one 
modality (Kantarci et al., 2012; Weingarten et al., 2015). 
 
Artificial intelligence and big data 
We used machine learning in chapter 6, which is a current application of artificial 
intelligence based on algorithms that can learn from data and subsequently 
construct a model in order to make predictions or decisions without being explicitly 
programmed. Machine learning approaches are increasingly applied to MRI data 
to study neurodegenerative diseases. A promising unsupervised machine learning 
method that allows for the exploration of previously unidentified disease subtypes 
based on neuroimaging, is cluster-wise ICA (C-ICA) (Durieux, 2015). C-ICA aims to 
cluster subjects in a data-driven fashion into homogeneous groups based on 
similarities and differences in the functional connectivity patterns that characterize 
them. The functional connectivity patterns that are associated with these 
subgroups could further provide information about neurodegenerative diseases 
such as PD. Components of a thus identified cluster may serve as a marker for the 
differentiation of subtypes with differing patterns of abnormal functional 
connectivity and potentially distinct clinical symptom profiles. Possible extensions 
of the C-ICA model include applications to other types of data as EEG data 
(Durieux, 2015).  
 
Despite promising results of some studies, the use of machine learning in PD is still 
in its early stage. This is likely caused by the limited sample sizes (Arbabshirani et 
al., 2017). However, a unique international, multicenter clinical, imaging and 
biologic specimens dataset of PD patients has been collected, managed and made 
available by the Parkinson’s Progression Markers Initiative (PPMI) (Marek et al., 
2011). A recent study using PPMI data investigated strategies to handle challenges 
of large datasets, such as heterogeneity or missing data, and subsequently 
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produced models for PD classification and prediction (Dinov et al., 2016). Future 
studies can possibly provide additional insights on how to address availability, 
integration and analytics of big data to advance the usability of MRI of PD in clinical 
practice. 
 
Individual classification 
Advanced neuroimaging approaches are of special interest for their potential to 
characterize unique morphological characteristics and connectivity patterns of 
neurodegenerative diseases (Agosta et al., 2017). For example, due to the high 
availability of 3 Tesla MRI scanners, the analysis of hippocampal subfields has 
gained increasing attention (Agosta et al., 2017). We showed that regional 
hippocampal differences between DLB and PD may be important in the distinction 
between the two disorders in chapter 3. However, except for the model that was 
built to identify PD patients at an individual level in chapter 6, the results in this 
thesis cannot be applied to individual patients. Neuroimaging studies in PD have 
largely provided average estimates at a group level. Although these studies are 
valuable for the discovery of relevant disease markers, the discriminative ability at 
the individual level of these neuroimaging measures is typically not evaluated. 
Neuroimaging-based single-subject prediction of neurodegenerative diseases has 
gained attention in recent years. In PD, a study using machine learning for the 
analysis of resting-state fMRI data showed that it was possible to predict motor 
scores (Movement Disorder Society unified Parkinson's disease rating scale; MDS-
UPDRS - part III) on an individual patient level (correlation = 0.35, p = 0.001; mean 
sum of squares = 222.17, p = 0.002) (Hou et al., 2016). Another study showed that 
machine learning in combination with multimodal MRI data for the differentiation 
of PD patients with a non-postural instability and gait difficulty subtype from 
patients with a postural instability and gait difficulty subtype resulted an accuracy 
of 92.3% (specificity = 97.0%, sensitivity = 84.2% and AUC = 0.96) (Gu et al., 2016). 
These findings provide preliminary evidence that neuroimaging-based inference in 
the individual heterogeneity in clinical features, disease course, and treatment 
response of PD might be possible. 
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8 Nederlandse samenvatting 
 
Van het proefschrift “Nieuwe benaderingswijzen in beeldvorming van de hersenen 
bij patiënten met de ziekte van Parkinson”
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De ziekte van Parkinson  
De ziekte van Parkinson wordt gekenmerkt door traagheid van bewegen 
(bradykinesie), beven (tremor) en stijfheid (rigiditeit). Naast deze zogenaamde 
motorische kenmerken (i.e. met betrekking tot bewegen), zijn er ook niet-
motorische kenmerken van de ziekte, waaronder problemen met nadenken, 
stemmingsklachten, slaapstoornissen, slaperigheid overdag, reukstoornis en 
autonome stoornissen, zoals problemen met de spijsvertering of bloedsomloop. 
De ontstaanswijze van de ziekte van Parkinson is nog niet duidelijk. De motorische 
kenmerken van de ziekte van Parkinson worden in verband gebracht met het verlies 
van dopaminerge cellen in de substantia nigra (zwarte kern; zie afbeelding 1). 
Daarnaast verspreidt de ziekte zich door de rest van de hersenen, wat hoogst-
waarschijnlijk bijdraagt aan de niet-motorische kenmerken van de ziekte.  
 De mate, expressie en snelheid van verergering van klachten bij de ziekte 
van Parkinson kunnen sterk verschillen van persoon tot persoon. Dit ondersteunt 
dat er mogelijk subgroepen van patiënten met de ziekte van Parkinson zijn, die 
bepaalde kenmerken van ziekte delen. De identificatie van subgroepen zou kunnen 
leiden tot meer inzicht in het ziekteproces van de ziekte van Parkinson. Tot op 
heden is het niet goed gelukt om op basis van ziektekenmerken patiënten te 
verdelen in subgroepen. 
 
Dementie met Lewylichaampjes 
Dementie met Lewylichaampjes vertoont belangrijke gelijkenissen met de ziekte 
van Parkinson, zoals de hierboven beschreven motorische en niet-motorische 
kenmerken. Vooral in de beginfase kan dementie met Lewylichaampjes lastig te 
onderscheiden zijn van de ziekte van Parkinson. Het ziekteverloop van dementie 
met Lewylichaampjes is echter vaak sneller invaliderend dan bij de ziekte van 
Parkinson, en ook de tolerantie en werkzaamheid van medicatie kan verminderd 
zijn, wat maakt dat een goed onderscheid tussen beide aandoeningen belangrijk 
is. 
 
Onderzoeksdoel van dit proefschrift 
In dit proefschrift hebben we de hersenen van patiënten met de ziekte van 
Parkinson en dementie met Lewylichaampjes bestudeerd door middel van 
beeldvorming met magnetische resonantie (“magnetische resonantie imaging”; 
MRI). We hebben hierbij geavanceerde benaderingswijzen gebruikt, die mogelijk 
behulpzaam kunnen zijn bij het identificeren van om karakteristieke veranderingen 
in de hersenen van patiënten met de ziekte van Parkinson te identificeren, kunnen 
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helpen in de differentiatie van mogelijke subgroepen en bij kunnen dragen aan het 
onderscheid tussen de ziekte van Parkinson en dementie met Lewylichaampjes. 
 
 
Afbeelding 1 
 
 
Afbeelding 2 
 
Samenvatting van de bevindingen 
In hoofdstuk 2 hebben we zogenaamde structurele hersennetwerken onderzocht 
bij de ziekte van Parkinson. Dit zijn groepen hersengebieden die overeenkomsten 
in structuur van de grijze stof (zie afbeelding 2) vertonen. De resultaten in dit 
hoofdstuk laten zien dat specifieke netwerken achteruitgaan bij de ziekte van 
Parkinson ten opzichte van gezonde controlepersonen. Dit zijn de zogenaamde 
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cingulate cortex (cingulate hersenschors; zie afbeelding 1) netwerken. Achteruit-
gang van deze netwerken bleek geassocieerd met de ernst van met name niet-
motorische klachten, namelijk problemen met het denkvermogen en slaperigheid 
overdag.  
 
In hoofdstuk 3 hebben we onderzocht of er structurele verschillen te vinden zijn 
tussen de grijze stof van de hersenen van patiënten met de ziekte van Parkinson 
en patiënten met dementie met Lewylichaampjes. De resultaten van deze studie 
laten een kleinere hippocampus (zeepaardje; zie afbeelding 1) zien bij patiënten 
met dementie met Lewylichaampjes ten opzichte van patiënten met de ziekte van 
Parkinson, waarbij met name de kop en het middendeel van de hippocampus is 
aangetast.  
 
In hoofdstuk 4 hebben we de gesteldheid van de gehele witte stof (zie afbeelding 
2) in de hersenen van patiënten met de ziekte van Parkinson onderzocht. Zowel 
leeftijd als de ziekte van Parkinson tasten de witte stof aan. Daarom hebben we 
gekeken of leeftijd mogelijk een sterker effect heeft op achteruitgang van de witte 
stof in patiënten met de ziekte van Parkinson dan in gezonde controlepersonen. 
We hebben gevonden dat patiënten met de ziekte van Parkinson meer 
wittestofafwijkingen hebben dan gezonde controlepersonen, met name vóór in de 
hersenen gelokaliseerd en diep in de witte stof, dichtbij de hersenkamers (met 
hersenvocht gevulde holten in de hersenen; zie afbeelding 2). De achteruitgang 
van de witte stof met toename van de leeftijd is gelijk voor beide groepen. De 
hoeveelheid wittestofafwijkingen is geassocieerd met leeftijd, maar daarnaast ook 
met klachten van het denkvermogen en met balansproblemen. Deze 
wittestofafwijkingen zijn doorgaans met het blote oog zichtbaar. We hebben ook 
gekeken naar afwijkingen die niet met het blote oog zichtbaar zijn. Dit hebben we 
gedaan in de witte stof waarin geen wittestofafwijkingen gevonden zijn, dus in de 
witte stof die “gezond” lijkt te zijn. Hierbij hebben we geen verschillen tussen 
patiënten met de ziekte van Parkinson en gezonde controlepersonen kunnen 
vaststellen.  
 
In hoofdstuk 5 hebben we opnieuw netwerken in de hersenen bij patiënten met 
de ziekte van Parkinson onderzocht. Dit keer middels zogenaamde functionele 
netwerken. Deze bestaan uit hersengebieden in de grijze stof die samenhang 
vertonen in activiteitspatronen op functionele MRI, wat connectiviteit wordt 
genoemd. Het functioneren van deze netwerken wordt geassocieerd met 
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bepaalde hersenfuncties, zoals het denkvermogen. Allereerst hebben we de 
hersenen als één groot netwerk beschouwd. We hebben gevonden dat frontale 
(dit is het voorste deel van de hersenschors; zie afbeelding 2) en pariëtale (dit deel 
van de hersenschors is aan de achter/bovenzijde gelegen, van opzij gezien; zie 
afbeelding 2) een hogere connectiviteit vertonen met het totale hersennetwerk 
vergeleken met gezonde controlepersonen. In frontale en occipitale (dit is het 
achterste deel van de hersenschors; zie afbeelding 2) gebieden hebben we juist 
een lagere connectiviteit met de rest van het netwerk gevonden. Vervolgens 
hebben de we hersenen opgedeeld in acht bekende afzonderlijke functionele 
netwerken, en zagen we met name toegenomen connectiviteit bij patiënten met 
de ziekte van Parkinson, waaronder in het sensorimotore netwerk (geassocieerd 
met motorische taken) en in de visuele netwerken. Beide methoden tezamen 
wezen op het belang van een aantal gebieden die veranderde functionele 
connectiviteit vertonen, waaronder de posterieure cingulate cortex en de 
precuneus (zie afbeelding 1). Uit eerder onderzoek is gebleken dat dit sterk 
geconnecteerde hersengebieden zijn. De regionaal veranderde connectiviteit bij 
patiënten met de ziekte van Parkinson is niet geassocieerd met klachten van de 
ziekte, wat er mogelijk op duidt dat enkelvoudige veranderingen op het niveau van 
functionele connectiviteit niet per se gerelateerd zijn aan kenmerken van ziekte, 
maar een complexer effect hebben. 
 
In hoofdstuk 6 hebben we het gebruik van zogenaamd “machinaal leren” 
toegepast op functionele MRI-data voor individuele classificatie van patiënten met 
de ziekte van Parkinson. Bij machinaal leren worden computer-algoritmes gebruikt 
die zonder interventie van buitenaf leren van data. We hebben gevonden dat het 
mogelijk is om met deze benaderingswijze patiënten met de ziekte van Parkinson 
in redelijke mate te kunnen onderscheiden van gezonde controlepersonen op een 
individueel niveau.  
 
Afsluitende opmerkingen  
Structurele en functionele connectiviteit 
In dit proefschrift hebben we laten zien dat netwerkbenaderingen waardevolle 
inzichten kunnen opleveren in de structurele en functionele hersenarchitectuur van 
patiënten met de ziekte van Parkinson. Mogelijke laten neurodegeneratieve 
ziekten netwerk-gestuurd verval zien van specifieke hersengebieden. In hoofdstuk 
2 en 3 hebben we laten zien dat de hersenen van patiënten met dementie met 
Lewylichaampjes en patiënten met de ziekte van Parkinson, verval tonen van het 
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zogenoemde anterieure (voorste) en posterieure (achterste) cingulate cortexnet-
werk. Het anterieure cingulate cortexnetwerk vertoont overlap met een netwerk 
dat gevonden is in eerdere studies met patiënten met de ziekte van Parkinson. Dit 
eerder gevonden netwerk vertoont eveneens verval bij patiënten met de ziekte van 
Parkinson, wat geassocieerd is met een ernstigere vorm van de ziekte van 
Parkinson. Gezamenlijk laten deze bevindingen zien dat de cingulate cortex 
aangetast is bij de ziekte van Parkinson, en dat veranderingen in netwerken waarbij 
de cingulate cortex betrokken is, gerelateerd zijn aan ziekteprogressie. 
 Daarnaast hebben we veranderde functionele connectiviteit gevonden in 
hersengebieden van het structurele posterieure cingulate cortex-netwerk, namelijk 
in de precuneus en posterieure cingulate cortex (hoofdstuk 5). Deze structuren 
worden gezien als prominente gebieden in de hersenarchitectuur die een 
belangrijke rol spelen bij het integreren van informatie van diverse 
hersengebieden. Veranderingen in deze structuren hebben mogelijk dan ook grote 
gevolgen voor de werking van het totale hersennetwerk. In patiënten met de ziekte 
van Parkinson hangen veranderingen in de (functionele en/of structurele) 
connectiviteit van deze structuren wellicht samen met specifieke kenmerken van 
de ziekte. Wij hebben bijvoorbeeld in hoofdstuk 2 gevonden dat verval van het 
posterieure cingulate cortex netwerk gerelateerd is aan met name niet-motorische 
klachten. 
 
Leeftijd 
Diverse studies suggereren dat leeftijd een belangrijke rol speelt in de ziekte van 
Parkinson. Toename van de leeftijd is bijvoorbeeld geassocieerd met een snellere 
achteruitgang in motorische klachten en ernstiger klachten van het denkvermogen. 
Onze resultaten laten achteruitgang zien van de grijze stof in zowel patiënten met 
dementie met Lewylichaampjes als in patiënten met de ziekte van Parkinson, 
vergeleken met gezonde controlepersonen. De gebieden die achteruitgang laten 
zien, zijn gebieden die vaak ook achteruitgaan met toenemende leeftijd, zoals de 
hippocampus en cingulate cortex. Verder hebben we regiospecifieke 
achteruitgang van functionele connectiviteit van met name de precuneus en 
posterieure cingulate cortex gevonden. Dit zijn gebieden zijn waarvan bekend is 
dat de functionele connectiviteit vaak aangetast wordt met toename van de 
leeftijd. Deze resultaten suggereren dat de ziekte van Parkinson gebieden aantast 
die al aangedaan zijn door het verouderingsproces, of dat het leeftijdseffect op de 
hersenen beïnvloed wordt door ziekte. Onze resultaten in hoofdstuk vier laten zien 
dat wittestofafwijkingen mogelijk al aanwezig zijn in een vroeg stadium van de 
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ziekte van Parkinson, wat andere wittestofstudies naar de ziekte van Parkinson 
ondersteunen.  
 
Dopaminerge medicatie 
De patiënten in dit onderzoek gebruikten tijdens deelname hun normale medicatie 
voor de ziekte van Parkinson (dopaminerge medicatie), met uitzondering van een 
groep patiënten die (nog) nooit medicatie had gebruikt. Het gebruik van 
dopaminerge medicatie tijdens een MRI-scan kan problematisch zijn, omdat dit de 
interpretatie van met name functionele data kan bemoeilijken. Er zijn aanwijzingen 
dat dopaminerge medicatie functionele connectiviteitsveranderingen die 
geassocieerd zijn met symptomen van de ziekte van Parkinson, normaliseert. Dit 
zou betekenen dat de veranderingen die we gevonden hebben, nog 
uitgesprokener zouden zijn als de patiënten geen medicatie zouden hebben 
genomen. Daarnaast zijn er mogelijk kleine functionele connectiviteits-
veranderingen die niets te maken hebben met symptomen van de ziekte van 
Parkinson. Het gebruik van dopaminerge medicatie door patiënten tijdens een 
MRI-scan heeft echter ook voordelen, zo is er minder kans op verstoringen van de 
scan door beweging. Ook veroorzaakt chronisch gebruik van dopaminerge 
medicatie waarschijnlijk langdurige functionele connectiviteitsveranderingen die 
niet verdwijnen als iemand kortdurend stopt met medicatie, wat eveneens de 
interpretatie van data kan bemoeilijken. Beide methoden hebben dus voor- en 
nadelen en het is belangrijk de dopaminerge status van patiënten te overwegen 
bij de interpretatie van MRI-data. 
 
Studiepopulatie 
Voor sommige studies beschreven in dit proefschrift was het gebruik van een 
controlegroep vereist. Gezonde controlepersonen zijn geselecteerd uit de Leiden 
Lang Leven studie. Er zijn een aantal kleine verschillen in enkele verzamelde 
variabelen en de methode van dataverzameling. Zo zijn patiënten met de ziekte 
van Parkinson gescand met een andere hoofdspoel dan de gezonde 
controlepersonen. Hier is rekening mee gehouden met de keuze van data-analyse, 
maar het kan van invloed geweest zijn op de bevindingen. Patiënten en 
controlepersonen kwamen overeen in leeftijd en geslachtsverdeling op 
groepsniveau, omdat het bekend is dat leeftijd en geslacht een belangrijke invloed 
hebben op MRI-kenmerken van de hersenen. In hoofdstuk vier hadden we graag 
patiënten en controlepersonen verzameld die daarnaast overeenkwamen in 
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cardiovasculair risicoprofiel, al bleken beide groepen uiteindelijk niet te verschillen 
in de verzamelde cardiovasculaire risicofactoren. 
 
Toekomstperspectieven 
Opkomende methodes van data-analyse 
In dit proefschrift hebben we vijf verschillende MRI-sequenties (verschillende 
soorten MRI opnamen) gebruikt. Hierdoor waren we in staat hersengebieden te 
vinden die zowel veranderde structurele als functionele connectiviteit hadden, 
zoals de cingulate cortex. Het combineren van structurele en functionele MRI 
wordt steeds vaker gebruikt om meer inzicht te verkrijgen in hersenveranderingen 
bij neurodegeneratieve ziekten. Daarnaast is het combineren van verschillende 
beeldvormende technieken (modaliteiten) in opkomst, zoals een combinatie van 
MRI met “positron-emissie tomografie” (PET; nucleair beeldvormend onderzoek, 
hierbij wordt een kleine hoeveelheid radioactieve stof gebruikt), “magneto-
encefalografie” (MEG; een techniek die magnetische velden gebruikt om de 
hersenactiviteit in kaart te brengen) en/of “elektro-encefalografie” (EEG; 
elektrische meting van hersenactiviteit). Het is aangetoond dat een combinatie van 
modaliteiten patiënten met dementie met Lewylichaampjes beter onderscheidt 
van patiënten met de ziekte van Alzheimer dan data van één modaliteit dat doet. 
 In hoofdstuk 6 gebruikten we machinaal leren, een vorm van kunstmatige 
intelligentie die toenemend wordt gebruikt wordt in MRI-studies om 
neurodegeneratieve aandoeningen te bestuderen. Een nieuwe toepassing van 
machinaal leren is de exploratie van nog onontdekte subtypes van ziekte op basis 
van functionele MRI-data. Componenten van op deze wijze geïdentificeerde 
subtypes kunnen mogelijk dienen als marker voor de differentiatie van subgroepen 
met verschillende patronen van abnormaal functionerende connectiviteit en 
potentieel verschillende klinische profielen. In de toekomst kan deze techniek 
mogelijk toegepast worden op andere datasoorten, zoals PET, MEG of EEG-data. 
Het gebruik van machinaal leren bij de ziekte van Parkinson staat nog in de 
kinderschoenen. Dit wordt waarschijnlijk mede veroorzaakt door gelimiteerde 
aantallen personen die meedoen aan MRI-studies. Een recent initiatief heeft echter 
een grote groep patiënten met de ziekte van Parkinson verzameld (Parkinson’s 
Progression Markers Initiative; PPMI) en onderzoekt daarnaast strategieën om met 
grote datasets om te gaan. Toekomstige studies kunnen inzicht bieden in zaken als 
beschikbaarheid, integratie en analyse van grote datasets om de bruikbaarheid van 
MRI in de klinische praktijk van de ziekte van Parkinson te verbeteren. 
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Individuele classificatie 
Geavanceerde beeldvorming van de hersenen biedt potentie om unieke 
hersenkenmerken van neurodegeneratieve aandoeningen in kaart te brengen. Zo 
is er bijvoorbeeld meer aandacht voor de analyse van deelgebieden (zoals ook in 
hoofdstuk 3 beschreven is) van de hippocampus door de toenemende 
beschikbaarheid van 3 Tesla MRI-scanners. MRI-studies zijn echter vaak uitgevoerd 
op groepsniveau, waardoor ze niet direct bruikbaar zijn voor de individuele patiënt. 
Ook in dit proefschrift zijn de resultaten die we rapporteren op groepsniveau, met 
uitzondering van de resultaten in hoofdstuk 6. De laatste jaren is er meer aandacht 
voor de toepassing van studieresultaten op individueel niveau. Enkele studies bij 
patiënten met de ziekte van Parkinson tonen interessante resultaten op individueel 
niveau. Een studie gebruikte machinaal leren voor de analyse van functionele MRI 
en liet zien dat het mogelijk was om het niveau van functioneren van het bewegen 
te voorspellen van individuele patiënten met de ziekte van Parkinson. Een andere 
studie gebruikte machinaal leren in combinatie met multimodale MRI-data en was 
zo in staat om op individueel niveau patiënten met de ziekte van Parkinson bij wie 
balansproblemen op de voorgrond stonden, te onderscheiden van patiënten bij 
wie dit niet zo was. Deze bevindingen geven hoop dat beeldvorming van de 
hersenen tot hulp kan zijn bij de individuele verschillen in symptomen, ziekte-
verloop en respons op behandelingen bij patiënten met de ziekte van Parkinson. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  114 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  115 
9  
 
Appendices 
 
Abbreviations 
References 
List of publications 
Dankwoord 
Curriculum vitae 
Abbreviations 
 116 
ABBREVIATIONS 
 
AD Alzheimer’s disease 
Alpha-SynA Alpha-synuclein aggregates 
AUC Area under the curve  
BOLD Blood oxygen level dependent 
C-ICA Cluster-wise independent component analysis 
DA Dopamine agonists 
DLB Dementia with Lewy bodies 
DMN Default mode network 
DTI Diffusion tensor imaging 
DWI Diffusion-weighted imaging 
ECM Eigenvector centrality mapping 
EEG Electroencephalography 
FA Fractional anisotropy 
FFC Full correlation functional connectivity 
FFD Full correlation functional connectivity dynamics 
FLAIR Fluid attenuated inversion recovery 
fMRI Functional magnetic resonance imaging 
FOV Field of view 
FSL FMRIB’s software library 
FWE Familywise error 
ICA-AROMA Independent component analysis based automatic removal of 
motion artifacts 
LDE-Dopa Levodopa dose equivalent of daily levodopa 
LLS Leiden Longevity study 
LUMC Leiden University Medical Center 
MC-FLIRT Motion correction FMRIB’s linear image registration tool 
MD Mean diffusivity 
MDS-UPDRS Movement Disorder Society unified Parkinson's disease rating 
scale 
MEG Magnetoencephalography 
MMSE Mini-mental state examination 
MNI Montreal Neurological Institute 
MTI Magnetization transfer imaging 
MTR Magnetization transfer ratio 
NAWM Normal appearing white matter 
Abbreviations 
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PD Parkinson’s disease 
PET Positron-emission tomography 
PFC Partial correlation functional connectivity 
PFD Partial correlation functional connectivity dynamics 
PPMI Parkinson’s progression markers initiative 
PROPARK Profiling Parkinson's disease 
ROC Receiver operator characteristic 
SCN Structural covariance network 
SCOPA-COG Scales for outcomes in Parkinson's disease - cognition 
SCOPA-PC Scales for outcomes in Parkinson's disease – 
psychiatric complications 
SENS-PD Severity of non-dopaminergic symptoms in Parkinson’s disease 
SIENAX Structural image evaluation using normalization of atrophy 
cross-sectional 
SMA Supplementary motor area 
TBSS Tract-based spatial statistics 
TE Echo time 
TFCE Threshold-free cluster enhancement 
TR Repetition time 
VBM Voxel-based morphometry 
WMH White matter hyperintensity 
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perspectief.
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